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 Abstract:  
Title: A study of clinical profile of severe sepsis in children and the association, if  
 any, of  urinary Liver Type Fatty Acid(L-FABP)  with mortality, morbidity and  
 diagnosis of  acute kidney injury.   
  Department: Department of Pediatrics, Christian Medical College, Vellore. 
  Name of the candidate: Dr. Merlyn Nisha. J 
  Degree and Subject: MD Pediatrics  
  Word count: 428  
  Background:  Severe sepsis has a worldwide incidence of 8.2% and is the most 
common cause of admission to Pediatric ICU.  Sepsis-associated AKI is the leading cause 
of mortality amongst children. Many biomarkers have been tried for early diagnosis of 
AKI; one such is L-FABP reported to be useful in predicting AKI, mortality and multi-
organ dysfunction in children with severe sepsis.  
  Objectives:  (1) To study the clinical profile of severe sepsis and identify risk factors 
associated with poor outcome (2) To measure the levels of urinary L-FABP in children 
with severe sepsis (3) To assess the association of LFABP in the diagnosis of AKI (4) To 
assess the correlation between urinary L-FABP levels and PELOD score in predicting 
mortality (5) To compare the levels of urinary L-FABP in survivors and non-survivors of 
severe sepsis.  
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Design: Prospective- observational study  
Materials and methods:  The study was conducted between January 2017 and August 
2017 in PICU. A total of 47 children with severe sepsis were enrolled .Their clinical 
course and outcome was recorded.  Serum Creatinine was done at admission and on a 
daily basis thereafter. Urine specimen was collected for L-FABP assay within 4 hours of 
admission and once at 48 hours and stored at -20c till analysis by a commercial ELISA 
kit (Hycult Biotech, USA- Cat # HK 404-01). The obtained data was analysed using 
appropriate statistical tools.   
Results 
A total of 47 children were admitted with severe sepsis. The incidence of severe sepsis 
was 7.5 % (47/650).  Fever was the commonest symptom present in 76.5%. Primary 
sepsis was present in 40/47(85%) and secondary sepsis in 14.8%. Blood culture was 
positive in 13/47(27.6%). The commonest organism was Pseudomonas. Acute Kidney 
Injury was present in 53.1% (25/47). Only oliguria was found to be a significant risk 
factor for AKI (p = 0.043). The mortality in children with Sepsis-associated AKI (SA-
AKI) was 66.7% (16/24), while the overall mortality was 51.1%(24/47).  The median 
value of L-FABP in children with AKI was 39.42(7.64-190.35) at baseline and at 48 
hours was 24.05(4.5-114.05).  L-FABP levels at admission were significantly elevated in 
non-survivors of severe sepsis compared to survivors (p=0.048).  PELOD score had a 
significant correlation with mortality (p<0.001).   
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Conclusion:  Acute Kidney injury remains a significant cause of morbidity in children 
with severe sepsis and mortality remains high.  L-FABP estimation levels at admission 
are predictive of non-survival in children with severe sepsis. It is  also a predictor of 
MODS.  PELOD was confirmed to be a good score to assess mulit-organ dysfunction and 
AKI.   
 
Key words: severe sepsis, acute kidney injury, liver-type fatty acid binding protein   
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INTRODUCTION  
Severe  sepsis  with  a  reported  global  prevalence  of  8.2%  is  one  of  the  most    
common  cause  of  admissions  to  Paediatric  Intensive  care  unit(ICU)(1). The   
mortality continues  to  be  high  with   development  of  multi-organ  dysfunction and  
acute  kidney injury(AKI)  being  major  among  them.  Early   diagnosis of AKI may 
significantly improve   the outcome   and decrease mortality.  Diagnosis of acute   kidney  
injury, by  definition  is  dependent  on serum  creatinine.  Serum creatinine is marker of  
renal function  and  not  injury. With  homeostatic  mechanisms  in  play  the  rise  in 
serum  creatinine  levels  does  not  happen  until  substantial  renal  injury  has  happened  
Hence an early   marker  of  renal  injury  is  preferred.   Several promising biomarkers 
have already been reported in literature and many more are under way.       
In recent times,  biomarkers  are  being   evaluated  as  early  indicators  of   AKI,  some  
of  which  appear  more  promising than others.  Liver-type Fatty acid binding  protein 
(L-FABP)  is  one such  promising  biomarker  for  early  detection  of  AKI.  Literature ,  
though  limited  shows  L-FABP to be a  promising  biomarker  which is not only as an  
early  indicator  of  renal  injury but also for predicting mortality in patients with severe 
sepsis.   
The  outcome  of  this  study  will  document  the  clinical  profile  of  children  with  
severe sepsis  and  identify   factors  associated  with  poor  outcome/mortality  in  the  
Indian  context.  In  addition  the  association  of  L-FABP as  a  predictor  of  mortality   
and  early  indicator   of  renal  dysfunction  in  sepsis  will  be  known.  Since  multiple  
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organ  dysfunction (MODS)  is  in itself a predictor  of  mortality  and   is   associated  
with  poor  outcome,  having  a scoring  system  to  measure  the  risk  of  MODS   helps  
in  improving  the  outcome.  In  our  study  we  propose to  use   the  Paediatric   logistic  
organ  dysfunction  score (PELOD)  to  predict  the  risk  of  organ  failure  and  
mortality.  Also,  the   correlation  of  PELOD  scores   with   L-FABP  levels,  if  any,  
will   indicate  the   utility  of  this  biomarker  if  not  as  a replacement  but   as  an  
additional  tool  for  detecting  organ  dysfunction in children with severe sepsis.  
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AIMS   AND  OBJECTIVES  
Aims: 
This  study  aims  to  compile  the  clinical   profile  of  severe  sepsis  in children  to  
identify  factors   associated   with  poor  outcome.  The  association,  if  any,  of  a  
urinary  biomarker (L-FABP)  with  poor   outcome/mortality   as  well   as  diagnosis  of  
AKI  will  also  be  assessed.    
Objectives : 
Primary   outcome : 
1. To  study  the  clinical  profile  of  severe sepsis  and  identify  factors   associated  
with  poor  outcome (mortality  and  morbidity)  in  children 
2.  To  measure  the  urinary  levels  of  Liver-type  fatty  acid  binding   protein(L-
FABP)  in  children  with  severe  sepsis 
3. To assess  the  association,  if  any,  between  L-FABP  and  diagnosis  of  acute  
kidney  injury   in  the  study  population 
 Secondary   outcome: 
1. To  assess  the  correlation  between urinary  L-FABP levels  and PELOD  score 
(Paediatric  logistic  organ  dysfunction score) 
2.  To compare  the  levels  of  urinary  L-FABP  in children  with  severe  sepsis  
amongst  survivors   and  non-survivors     
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LITERATURE REVIEW:   
Sepsis is the most common cause of death in infants and children worldwide. The global 
prevalence of severe sepsis is 8.2% and it is one of the most common causes of admission 
to Pediatric Intensive care unit (1). Sepsis is defined as life-threatening organ dysfunction 
caused by a dysregulated host response to infection (1). It is one of the most serious and 
potentially life-threatening infectious diseases in childhood.    
SEVERE SEPSIS IN CHILDREN:   
Sepsis is a clinical syndrome resulting from a dysregulated systemic inflammatory 
response to infection (1).  It is characterized by a generalized pro-inflammatory cascade, 
which may lead to widespread tissue injury.  It encompasses a clinical spectrum of 
severity, including severe sepsis, septic shock and multi-organ failure (2).  Sepsis is a 
leading cause of morbidity and mortality worldwide.   The largest epidemiological 
reports of the incidence of severe sepsis in children come from US cohort studies which 
was done by Watson RS et al and Hartman ME et al, published in the year 2003 and 2013 
respectively(5). These studies show a rising annual incidence of severe sepsis over this 
period of time (0.56 to 0.89/1000 children) across all age groups.  The incidence of 
severe sepsis in these cohorts was significantly higher in younger age groups (incidence 
in the neonatal age group and infants aged <1 year was 9.7 and 2.25 cases per 1000 
children respectively)(5).     
International consensus  definitions for Pediatric sepsis defines sepsis is as shown below:  
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TABLE 1.INTERNATIONAL CONSENSUS DEFINITION FOR PEDIATRIC 
SEPSIS 
Ref :  Nelson Textbook of pediatrics,  20
th
  Edn  
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INCIDENCE AND ETIOPATHOGENESIS:  
Bone et al in 1997 proposed a new hypothesis for pathogenesis of the disease process of 
sepsis, which put forth the idea that the initial inflammatory response gave way to a 
subsequent “compensatory anti-inflammatory response syndrome”(7). The infection 
triggers a much more complex, variable and prolonged host response, in which both pro- 
inflammatory and anti-inflammatory mechanisms can contribute to clearance of infection 
and tissue recovery on one hand and organ injury and secondary infections on the 
other(7). The pro-inflammatory reactions are responsible for collateral tissue damage, 
whereas the anti-inflammatory responses are implicated in the enhanced susceptibility to 
secondary infections(3).  
In the United States, severe sepsis is recorded in 2% of all patients admitted to the 
hospital. Half of these patients are treated in the intensive care unit, representing 10% of 
all ICU admissions(4). Adhikari et al in a study done in adults on critical care and the 
global burden of critical illness estimated the incidence rates of sepsis in the United states 
as upto 19 million cases worldwide per year.  Severe sepsis occurs as a result of both 
community-acquired and health care-associated infections. Blood cultures are typically 
positive in only one third of cases, and in upto a third of cases cultures from all sites are 
negative.  An epidemiologic study of sepsis showed that during the period from 1979 to 
2000, gram –positive infections overtook gram-negative infections (6).  However in a 
more recent study  done by Vincent et al in 2009 about the prevalence and outcome of 
infection in intensive care units involving 14,000 ICU patients in 75 countries done in 
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adults, gram-negative bacteria was isolated in 62% of patients with severe sepsis, gram-
positive bacteria was isolated in 47% and fungi in 19%.(9)    
Risk factors for sepsis are related both to a patient’s predisposition for infection and to 
likelihood of acute organ dysfunction if infection develops  (10).  The well known risk 
factors that most commonly precipitate severe sepsis and septic shock include age, sex, 
race, ethnicity, chronic diseases like acquired immunodeficiency syndrome, other co-
morbidities like- cardiovascular, hematologic/immunologic, malignancy,  post solid 
organ/stem cell transplant(10).   
 
Schlapbach et al in a multicentre retrospective cohort study done between 2002-2013, 
about the mortality related to  invasive infections, sepsis and septic shock in critically ill 
children in Australia and New Zealand,  showed that the factors significantly associated 
with mortality in pediatric sepsis were oncological conditions (OR 1.95, 95% CI 1.41-
2.69),  cardiovascular conditions(OR 1.41, 95% CI 1.33-1.50), bone marrow 
transplantation (OR 2.80, 95% CI 1.76-4.44), chronic neurological disorder (OR 1.76, 
95% CI 1.23-2.52), chronic renal failure (OR 3.22, 95% CI 1.43-7,24)(10) . The mortality 
rate was however highest in children with solid organ/stem cell transplant (48.2%), 
followed by malignancies (41.3%), renal diseases (38.2%), hematologic/immunologic 
conditions (37.7%). This study also showed that the most common sites of infection are 
respiratory tract (57.2%) and bloodstream infections (67.8%).(11)  
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 Children  less  than  12  months  have  the  highest  risk  of  death  from blood stream  
infections. Indwelling  vascular  lines,  urinary  catheters, endotracheal  tubes and other  
foreign  materials  further  predispose  already  compromised  children to  nosocomial  
infections.(12)  Certain  organisms  are  associated  with  poor  prognosis, particularly  
fungi,  infections  with  antibiotic  resistant  bacteria  and  hospital-acquired  pathogens.  
Ruth et al in a  multicentre database study done from 2002 to 2012, on the current trends 
and outcomes from the  pediatric health information systems database stated that the 
proportion of severe sepsis in children with at least  one  co-morbidity has been 
increasing from 64.9% in 2002 to 76.6% in 2012 (p<0.0001).(13) 
ORGAN DYSFUNCTION IN SEPSIS: 
Organ dysfunction is the presence of altered organ function such that the homeostasis 
cannot be maintained without intervention. The  criteria  to  diagnose  organ  dysfunction  
in  infants  and  children  were  first  described  by  Proulx  et al  in 1996  and  updated  in 
2005  by  Goldstein et al.   
The organ-dysfunction variables include arterial hypoxemia (ratio of the partial pressure 
of arterial oxygen to the fraction of inspired oxygen <300), acute oliguria (urine output 
<0.5ml/kg/hr), increase in creatinine level of > 0.5mg/dl, coagulation abnormalities (INR 
>1.5, APTT>60 secs), paralytic ileus (absence of bowel sounds), thrombocytopenia 
(platelet count <1,00,000/mm
3
) and hyperbilirubinemia (total bilirubin >4mg/dl).(14)   
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Although the mechanisms that underlie organ failure in sepsis have been only partially 
elucidated, impaired tissue oxygenation plays a key role. Several factors – including 
hypotension, reduced red-cell deformability and microvascular thrombosis –contribute to 
diminished oxygen delivery in septic shock. Inflammation can cause dysfunction of the 
vascular endothelium, accompanied by cell death and loss of barrier integrity, giving rise 
to subcutaneous and body-cavity edema. (16) 
 
In addition mitochondrial damage caused by oxidative stress and other mechanisms 
impairs cellular oxygen use. Moreover injured mitochondria release alarmins into the 
extracellular environment, including mitochondria DNA and formyl peptides, which can 
activate neutrophils and cause further tissue injury.(17) 
 
 The  factors  which  account  for  poor  prognosis  in children  with  septic  shock  
include  time  lag  to  PICU transfer, length of PICU  stay, presence  of  multi-organ   
dysfunction,  poor  paediatric  risk  of  mortality score  at admission,  prediction  of 
patient  outcome  at admission to  PICU  is  not  only  important  in counseling parents  
but  also  for  the  optimum  utilization  of  limited  resources.  (18) 
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FIGURE 1.THE ORGAN FAILURE IN SEVERE SEPSIS AND DYSFUNCTION 
OF THE VASCULAR ENDOTHELIUM AND MITOCHONDRIA :  
Ref : N ENGL J MED 369;9 august 29, 2013  
Many  studies have  analysed  risk  factors  for  death  in  various  clinical  syndromes  
associated  with  septic  shock.  Despite  appropriate  therapy  in  many  circumstances, 
the  multiple  organ  dysfunction  syndrome  develops  in  many  cases.  In  this  
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syndrome,  there  is  variable  involvement  of  many  organs,  such  as ongoing  shock  
from  cardiovascular  dysfunction,  acute  tubular  necrosis,  respiratory  failure, hepatic  
dysfunction, encephalopathy and  coagulopathy.(19)  Studies  reveal  that  non survivors  
of  sepsis  had  significantly  marked  derangement  of  renal, hepatic  and  coagulation 
profile, higher requirement  of  inotropes and  larger number  of  multiple  organ  
dysfunction and  are  important  risk  factors  for  mortality  in combination.   
MODS SCORE IN ICU: 
Several  scoring  systems  for  measuring  Paediatric  MODS  have been  described  in  
the  literature  which  include  PRISM (Paediatric  risk  of  mortality), PELOD (Paediatric 
logistic  organ  dysfunction), PIM (Paediatric index of  mortality), PEMOD (Paediatric  
multiple  organ  dysfunction) scores. PELOD  score  has  been  validated  in a  multi-
centre  study, risk  of  mortality  was  directly  proportional  to  the  degree of  organ  
dysfunction  and  the  score  increased  with  each  organ  dysfunction. The   PELOD  
score  has  12  variables  and  six  organ  dysfunctions, and the  most abnormal  value  
each  day was  used  to calculate the score. The AU-ROC curve ranged  from  0.79 to 
0.85  during the  first  5 days  and  the discrimination was  0.91 ±0.01 which  was quite 
good.    
PELOD  score  was significantly  higher  in  non-survivors  than  in  survivors  and  
there  was  a  significant  correlation  of the  score  with  mortality. Marshal and  
colleagues put  forth the  approach  to  create  and  validate  the  multiple  organ  
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dysfunction  score, which  has been  put  forward  for  inclusion  in  the  assessment  of  
sepsis.  
 
TABLE 2. PEDIATRIC LOGISTIC ORGAN DYSFUNCTION SCORE: 
Ref: The lancet 2003-validation of the PELOD score  
24 
 
SEPSIS-ASSOCIATED ACUTE KIDNEY INJURY: 
Acute kidney injury is a frequent and serious complication of sepsis in intensive care unit 
(ICU) patients as per Lafrance et al in a study done in ICU set-up in 2010 on acute kidney 
injury associates with increased long-term mortality. There is strong evidence that sepsis 
and septic shock are the most important causes of AKI in critically ill patients account for 
50% or more cases of AKI in ICUs and associate with a very high mortality.  
 
It is well established that kidney is a commonly affected organ during sepsis, and its 
involvement carries a high risk of mortality. The patho-physiology of AKI in sepsis is 
complex and multi-factorial and includes intrarenal hemodynamic changes, endothelial 
dysfunction, infiltration of inflammatory cells in the renal parenchyma, intra-glomerular 
thrombosis and obstruction of tubules with necrotic cells and debris. A  growing evidence 
now suggests that sepsis-associated immune responses involve the activation, in a 
sequential manner, of both pro and anti-inflammatory mechanisms.   
After initial host-microbial interaction, there is wide-spread activation of innate immune 
response, which co-ordinates a defensive response involving both humoral and cellular 
components. This in turn leads to secretion of various cytokines, most importantly IL-1, 
TNF-α, IL-6 that progress to a state of cytokine storm, hemodynamic instability, and 
eventually organ dysfunction and septic shock. (20) 
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This pro-inflammatory phase is followed by a compensatory anti-inflammatory response; 
an immunosupressed state characterized by altered cytokine production and antigen 
presentation by monocytes, decreased lymphocyte proliferation and increased apoptosis. 
Recent studies suggest an anti-inflammatory role for soluble thrombomodulin in AKI  
and release of stem cell factor by MMP-9 has an anti-apoptotic effect through activation 
of cKit. (22)  
Toll like receptors (TLR) are a class of proteins that play an important role in altering the 
innate immune system. Modulation of TLRs may become a novel therapeutic target 
especially in the treatment of organ injury accompanying sepsis. Arterial vasodilatation 
with an associated decrease in systemic vascular resistance is a fundamental hallmark of 
sepsis. (25) 
The characteristic pattern of renal blood flow (RBF) in human sepsis is for the most part 
largely unknown because RBF cannot be measured continuously in humans, and even its 
intermittent measurement requires a high level of invasiveness. Afferent and efferent 
arterioles are essential regulators of renal perfusion. Simultaneous dilation of both 
arterioles can lead to decreased glomerular capillary pressure and subsequent decrease in 
filtration. This is very similar to the observed effects of angiotensin-converting enzyme 
inhibitors and may account for the AKI that accompanies sepsis.  
FIGURE 2.SHOWS THE KEY PATHOGENIC PATHYWAYS IN SEPSIS 
INDUCED AKI 
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Ref:J
ournal of the American society of Nephrology 22:99-106, 2011  
 
 
BIOMARKERS IN SEPIS-ASSOCIATED AKI: 
Septic AKI is characterized by a distinct pathophysiology and important differences exist 
in patient characteristics, response to interventions and clinical outcomes. This may also 
extend to unique patterns of plasma and urinary biomarkers in septic AKI. For instance 
the excretion of IL-18 is higher in septic AKI than in non septic AKI. The increased level 
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of IL-18 predicts deteriorating kidney function approximately 24 to 48 hours before 
clinically significant AKI(24). Moreover sepsis decreases production of creatinine 
without major alterations in body weight, hematocrit or extracellular fluid and creates 
further limitations on using changes in creatinine levels as a reliable marker of AKI. 
Hence it is essential to have markers that enable early detection of AKI. The utility of 
these novel biomarkers including Cystatin C, Neutrophil gelatinase –associated lipocalin,  
Liver type fatty acid binding protein, netrin-1 for early detection of sepsis-induced AKI is 
very encouraging and may have prognostic implications as well.(28)  
For instance urinary liver type fatty acid-binding protein (L-FABP) is significantly higher 
in AKI associated with sepsis than in non-AKI in adult ICU patients as per study done by 
Nakamura et al on urinary liver-type fatty acid binding protein in septic shock in 2009 
which was a prospective cohort study in adult ICU patients. 
 L-FABP  has  been  shown  to  detect  renal  injury  earlier  than  creatinine and also  
predicts mortality and poor outcome in children with severe sepsis as per Doi et  al, in his 
prospective observational study in post-surgical patients in ICU with AKI done in 2010.   
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Table 3.LIST OF EMERGING BIOMARKERS-IN SEVERE SEPSIS:  
Ref
: J Am Soc Nephrol 22 :999-1006, 2011   
LIVER TYPE FATTY ACID BINDING PROTEIN (L - FABP): 
Liver-type fatty   acid  binding  protein(L-FABP), one  such  candidate  biomarker,   
which is a 14kDa protein, is  expressed  in  the proximal  tubular epithelial  cells,  
hepatocyte and crypt to  villus  tip  of   intestine.  This endogenous antioxidant promotes   
free fatty acid metabolism by  binding long-chain  fatty acid  oxidation products. L-FABP  
is  bound  to  serum albumin and is  reabsorbed into  proximal  tubule bound to  serum  
albumin. Filtered L-FABP is  taken up  proximal  tubule and  acts as  a carrier protein   
and  transports free  fatty  acids to  mitochondria  and  peroxisome  for  metabolism.   
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Upon stress and ischemia-reperfusion injury  there is  an  upregulation of L-FABP, which  
binds lipid hydro-peroxides and other  reactive  oxygen  species which  together  is   
released into  urine(30).  
FIGURE 3.SHOWS THE SITE OF SECRETION OF L-FABP: 
 
Ref:L-FABP and kidney disease 2014  
Urinary L-FABP could serve as a biomarker of AKI primarily in septic  patients   
presenting with shock and multiorgan  failure, in whom  the  potential  for  liver  
involvement could be present. Once in the proximal tubular cells, L-FABP may act as a  
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surrogate molecule to reduce lipid  peroxidative  stress during  reperfusion  by  binding  
fatty acid oxidation products  and  limiting  the  toxic  effects  of  oxidative intermediates  
on cellular  membranes.  L-FABP not only contributes to the trafficking of fatty acids  
but also  serves as  a diagnostic indicator  of  acute  renal diseases.   
ACUTE KIDNEY INJURY CRITERIA: 
Recognition of AKI   requires the delineation of easily measured criteria that can be  
widely applied. In September   2005, in a meeting in Amsterdam a new classification of   
AKI was proposed by the acute kidney injury network (AKIN) working group composed  
of nephrologists, critical care  physicians and other  physicians  specialized in AKI. The  
AKIN   classification was published in March 2007 in critical care, the diagnosis of   
AKI is considered only after achieving adequate status of hydration and after excluding   
Urinary  obstruction.  AKIN classification only relies on serum creatinine and not on  
GFR changes, baseline serum creatinine is not necessary and it requires at least two  
values of  serum creatinine obtained  within a period of 48 hours. It gives important  
information about the etiological diagnosis. AKIN classification allows identification  
and stratification of AKI in a large  proportion of hospitalized patients and  was   
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independently associated with the outcome. Patients with AKI had higher in-hospital  
mortality and longer  lengths of stay, AKI survivors were more likely to be discharged to  
an extended care facility. (35)  
The Acute dialysis quality initiative (ADQI) group for the study of AKI proposed the  
criteria for defining AKI, which was the pRIFLE (pediatric risk, injury, failure, loss and  
end stage renal disease)  in may 2004.  pRIFLE is based on serum creatinine and urine  
output determinants, it has largely been  validated in terms of determining the incidence  
of AKI and its prognostic stratification in several settings of hospitalized patients.  
However it has a number of limitations, since baseline creatinine is necessary to define  
and classify AKI , which is frequently unknown in clinical practice.(38)   
 
Hence to overcome the practical difficulties, in September 2005 a new classification of  
AKI was proposed by the Acute Kidney Injury Network (AKIN) working group. The  
AKIN classification which was published in march 2007, in which baseline serum  
creatinine is not necessary in the AKIN classification. It requires at least 2 values of  
creatinine obtained within a period of 48 hours.(40) 
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TABLE 4. AKIN CRITERIA:  
 
AKIN classification allows the identification and stratification of AKI in a large  
proportion of patients and was independently associated with outcome. This  
classification adds important etiological information. The integration of the new  
biomarkers of AKI into the clinical classification could increase the sensitivity and  
specificity of AKI diagnosis.   
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Renal replacement therapy: 
Renal support therapy has been used for treatment of sepsis associated acute kidney  
injury. Timing of initiation of renal replacement therapy is highly controversial, data  
suggest initiation of therapy before onset of overt complication and accumulation of  
significant fluid overload which may lead to improved survival. The ideal modality to  
support critically ill patients is still unclear. Continuous renal replacement  
therapy (CRRT) is used most commonly in critically ill unstable patients because of its  
adaptability  to patient condition and better physiologic and hemostatic control. 
Data suggest the early initiation of renal replacement therapy may facilitate better renal  
recovery and reduce long term risk of chronic kidney disease. CRRT possesses several  
distinct advantages over peritoneal dialysis and hemodialysis in the management of  
sepsis associated acute kidney injury. CRRT mimics the effects of renal function with its  
continual ultra filtration and solute clearance. It can deliver prescribed ultra filtration 
rates unlike  peritoneal dialysis. Hence this makes CRRT preferable for  provision  of   
renal  supportive  therapy as compared to other modalities especially in hemodynamically  
unstable fluid overloaded septic patients. Adequate nutritional delivery is  possible with  
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CRRT since there is no need  for fluid restriction and ultrafiltration  rates can be adjusted  
concomitantly with increased volume infusions associated with increased nutritional  
delivery. CRRT has additional benefit of restoring immunohemostasis by removing both  
proinflammatory and anti-inflammatory molecules during sepsis associated acute kidney  
injury.  Children with AKI and sepsis are often at risk for undernutrition. Renal  
supportive therapy can lead to loss of  free amino acids and peptides thereby leading to  
negative nitrogen  balance. Fluid restriction exacerbate the above condition by further  
contributing to  undernutrition. This may lead to reduced survival rates. CRRT has been  
used as a technique to deliver 100% recommended daily allowance either by enteral or  
parenteral   nutrition. (42)  
A multinational study done in 2000 by   Uchino et al showed that acute renal failure 
accounts for about 5.5 to 6% of all admissions to pediatric intensive care unit. Of the 
various causes septic shock accounted for 47.5%, major surgery 34%, cardiogenic shock 
25%, hypovolemia 26%, nephrotoxins 19%. Sepsis-associated AKI occurs in 
approximately 20% of patients with moderate sepsis and 50% in septic shock when blood 
cultures are positive. Opera et al in a German prevalence study on acute renal failure in 
patients with severe sepsis found a prevalence of 41.4%. (35) 
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Bailey et al in a prospective study to determine the incidence, risk factors and outcome of 
acute renal failure in critically ill children in a tertiary pediatric intensive care unit in  
Canada noted an AKI incidence rate of 4.5%. The most common diagnoses causing acute 
kidney injury were hemolytic uremic syndrome (18.2%), oncologic pathologies (18.2%) 
and cardiac surgery (11.4%). 
Medlina et al in a prospective study performed in 4 PICUs in Spain among children aged 
7 days to 16 years noted the incidence of acute kidney injury to be 2.5%. Bresolin et al 
studied 110 critically ill children admitted between 2002 and 2004 to an intensive care 
unit in Brazil and had acute kidney injury to define poor  prognostic factors in critically 
ill children. Thus an incidence of acute injury of 8% was noted in this study.  
Renal ischemia (21%) and sepsis (11%) were major causes of acute kidney injury in a 
retrospective study done in USA by Stickle et el on 248 children with acute kidney 
injury.  
In another retrospective study done by Agarwal et al in Christian Medical College, 
Vellore, among south Indian children, to assess the clinical profile of children admitted 
with acute renal failure and to identify factors associated with poor outcome, 54 children 
between one month and 12 years with acute renal failure were studied. Amongst the 
various precipitating causes of renal failure, proven sepsis was found in 22% of the 
children.  Mortality due to sepsis was 83%, of which mortality was 65% in patients who 
were on dialysis and 100% in those requiring ventilator support.  
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 Khilnani et al in his prospective observational study on the profile and outcomes of 
children admitted to a tertiary intensive care unit in India between January 1998 and 
December 2000, found the incidence of multi-organ dysfunction to be 18-25%. In the 
same study it was reported that diagnosis of various patients included (respiratory19.7%, 
cardiac 9.7%, neurological 17.9%, infections 12.5%, trauma 11.7%, other surgical 8.8%. 
He found the incidence of nosocomial infections to be 16.86%. Multi-organ failure 
remained the major cause of death according to this study and dengue and malaria were 
the common infections. (45) 
Gurpreet et al, Nikhil et al did a study on clinical outcome and predictors of mortality in 
children with sepsis, severe sepsis and septic shock which was a prospective 
observational study done in children aged one month to 14 years admitted to a tertiary 
care PICU in Rohtak, Haryana between November 2012 and February 2013.  
Hemodynamic and laboratory parameters which discriminate survivors from 
nonsurvivors were evaluated. A total of 50 patients were enrolled in the study of whom 
21(42%) were discharged (survivors) and rest 29(58%) expired (nonsurvivors). Duration 
of ICU stay (OR 95% CI: 1.18(0.99-1.25), time lag to PICU transfer (OR 95% CI: 
1.02(0.93-1.12), number of organ dysfunction (OR 95% CI: 0.03(0.01-1.53) p=0.08).  
This study stated that mortality among children with sepsis, severe sepsis and septic 
shock were not predicted by any individual factors including time lag to PICU transfer, 
duration of stay, presence of multi-organ dysfunction.  
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The SPROUT (The Sepsis Prevalence, outcomes and Therapies) study was a prospective 
cross-sectional study conducted in children less than 18 years with severe sepsis in 
PICUs across the world at 128 sites in 26 countries on 5 days throughout 2013-2014. Out 
of 6925 patients screened, 569 had severe sepsis (prevalence 8.2%, 95% CI:7.6-8.9%). 
This study showed that the most common sites of infection being respiratory (40%) and 
blood stream (19%). Common therapies included mechanical ventilation (74% patients), 
vasoactive infusions (55%), corticosteroids (45%).   Hospital morality was 25% and did 
not differ by age or between developed and resource-limited countries. Median 
ventilator-free days were 16(IQR 0-25), vasoactive free days were 23(IQR 12-28). 67% 
of patients had multi-organ dysfunction at sepsis recognition, with 30% subsequently 
developing new or progressive multiorgan dysfunction. Among survivors 17% developed 
at least moderate disability.   This large international study demonstrates that pediatric 
severe sepsis remains a highly prevalent public health problem in critically ill children 
and is associated with substantial morbidity and mortality.  
 
In a prospective observational study done in PICU of Cairo university, Mounira Pediatric 
hospital over one year which included 231 patients, to assess the severity of diseases and 
predicting mortality in ICUs by using scoring systems, the mortality rate was 6.4%-
10.3% in critically ill patients. There were positive correlations between PRISM III, 
PIM2, PELOD, PEMO D , SOFA  and TISS scores on the day of admission and mortality 
rate (p<0.0001).(45)   
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This study showed that risk of mortality was elevated in patients on  inotropes (OR-8.5).  
Also  insertion  of  central  venous  line  reflected severity  of  the  case  because risk  of  
mortality  was elevated (OR=6.9).  Mortality was high in  patients  with  liver  enzymes 
>250IU/L(OR-3.6; ALT 95% CI: 47.86-155; AST 95% CI 74.96-395.28), elevated  
bilirubin >6mg/dl (OR=12.8; 95% CI: 1.93-12.1)and  low albumin  (OR=4.4; 95% CI 
:3.1- 3.39). There was a significant relation between blood urea nitrogen and mortality 
(p=0.01). The  highest  risk  of  mortality  was  found  with  serum  creatinine  >5mg/dl 
(OR= 17  and  specificity  98.8; 95% CI: 0.67 -1.29).  Risk  of   mortality  increased  with  
low  platelet  count  ranging  from  1,00,000  to  1,49,000  (OR=3.7; 95% CI: 276.21-
371.26).  Mortality   doubled  in  patients  with  PT >22s  or  PTT > 57s (OR=6.5; PT 
95% CI: 20.22-42.67; PTT 95% CI: 39.69-132.58) and  was  100%  in  patients  who  
needed   anti-coagulation  treatment ( those  patients  of  post-cannulation  thrombosis).   
Risk  of  mortality  was  high  in  patients  with  potassium  >8meq/L (OR= 12.1; 95% 
CI:4.08-4.91) or  calcium from  5  to  6.9 mg/dl  (OR= 5.5; 95% CI: 8.17-9.03).   Risk  of  
mortality  increased  in  patients  with  metabolic  acidosis  (OR=12.7; specificity  97.7; 
pH 95% CI : 7.2-7.33), fever  and  hypothermia  (OR = 5.9;  specificity  99.4)  and  
patients  who  required more  than  one  peripheral  line  (OR=6; specificity 84.4).  
Persistent shock on admission to ICU is associated with increased odds ratio for death 
3.8.  For every hour of persistent shock, the  odds ratio for death  was 2.29 (95% CI:1.19 
to 4.44).    
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With  treatment  the  overall  mortality  is  approximately  10%  in  children  upto  19 
years  of age as  per  a  study  done  in   PICU  in  Birmingham children’s  hospital UK ,  
by  Adrian  Plunkett and  Jeremy  Tong between October 2008 to October 2013.  Patients   
with  pre-existing  disease  experience a higher mortality  of  12.8%  compared  with 
7.8%  in  previously  healthy  children. (45)    
          
  The Beginning, Ending Supportive Therapy for the Kidney,  a  large  prospective   
 observational study of  more than  29,000  patients in ICU at 54 hospitals in 23  
   countries across the world, from September 2000 to December 2001, in patients >12 
  years of age, to characterize differences in etiology, illness severity and clinical practice,   
  reported  an  AKI  incidence of   5.7%,  with  SA-AKI  being  the  highest  associated 
  etiology (47.5%).  Overall mortality was 60.3% (95% CI 58-62.6%).  This study  
 showed that the most common contributing factor to ARF was septic shock (47.5%  
95%CI :58.0-62.6%). Dialysis dependence at hospital discharge was 13.8% (95% CI  
 11.2-16.3%) for  survivors. Independent risk factors for hospital mortality include use  
 of vasopressors (OR1.95 95% CI: 1.50-2.55, p<0.001), mechanical ventilation (OR  
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 2.11, 95% CI 1.58-2.82, p<0.001), septic shock (OR 1.36 95% CI:1.03  
 1.79,P=0.03), cardiogenic shock (OR 1.41, 95%CI :1.05-1.90,p-0.02). (39)   
This study showed that the major reason for ICU admission was medical in 58.9% and  
surgical in remaining 41.1%. Cardiovascular surgery was the most common diagnostic  
grouping, followed by medical respiratory, medical cardiovascular, gastrointestinal tract  
surgery and sepsis. While 50% of ARF patients died in ICU another 8% died in the  
hospital after discharge from ICU. Of the patients who survived to hospital discharge, 
13.8% (95% CI: 11.2%-16.3%) required RRT at the time of discharge. The median  
length of ICU stay was 10days (IQR 5-22 days) and the median length of hospital stay  
was 22 days ( IQR 11-44 days). Based on this research the world-wide prevalence of  
acute RRT was approximately 4%.   
     
In a retrospective observational study done by Lopes et al JA in acute kidney injury in  
adults with sepsis in 2009, between Janunary 2004 and June 2007, a total  of  315 patients 
were studied. According to AKIN criteria, 99 patients (31.4%) had AKI : 26.2% at stage 
1, 20.2% at stage 2, 53.6% at stage 3. Four patients (1.9%) with no AKI progressed to 
stage 1, two patients (7.7%) at stage 1 progressed to stage 2,  one patient (3.8%) at stage 
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1 progressed to stage 3, and one patients at stage 2 (5%) progressed to stage 3. The 
mortality rate was 25.3% and increased from normal renal function to stage 3 (normal 
12.5%; stage 1, 34.6%; stage 2, 45%;stage 3, 64.1%; p<0.0001).  The predicted mortality 
in various stages include AKIN stage 1 (OR 3.03, 95% CI: 1.12-8.19,p=0.029), stage  2 
OR 3.3, 95% CI: 1.11-9.78,p=0.031) and stage 3 (OR 7.35, 95% CI: 3.13-17.25 , 
p<0.0001).  Hence based on this study they concluded that AKIN criteria was a useful 
tool to characterize and stratify septic patients according to the risk of death.   
In another retrospective study done by Agarwal et al among south Indian children, to 54 
children between one month and 12 years with acute renal failure were studied. Amongst 
the various precipitating causes of renal failure, proven sepsis was found in 22% of the 
children.  Mortality due to sepsis was 83%, of which mortality was 65% in patients who 
were on dialysis and 100% in those requiring ventilator support.   
A retrospective study was done by Nakamura et al done in adults to determine whether 
urinary liver-type fatty acid binding protein  levels altered in patients with septic shock or 
severe sepsis without shock among 40 cases and 30 controls in 2009, the results showed 
that the urinary L-FABP levels measured by ELISA method, were significantly higher in 
patients with septic shock(p<0.001), than in those without shock(p<0.05), patients with 
ARF (p<0.001), whereas serum L-FABP did not show any significant difference. Urinary 
L-FABP levels remained high for 7 days after initiation of conventional treatment 
(p=0.12). These results suggest that urinary L-FABP levels were significantly increased 
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in patients with septic shock.  The sensitivity and specificity of L-FABP for diagnosing 
AKI as against hospitalized controls, showed a sensitivity of 83% and specificity of 90%.   
In a cross-sectional study Ferguson et al studied the comparative values of multiple 
biomarkers used in the diagnosis of AKI. In a total of 92 patients with established AKI, 
they showed that the diagnostic ability of L-FABP  in diagnosing AKI in hospitalized 
patients was very good (ROC-AUC 0.93), as compared to other well-described 
biomarkers of AKI including NGAL (0.92), KIM-1(0.89), NAG(0.89) and IL-18(0.83).  
In this study L-FABP emerged as a significant predictor of RRT (p=0.02) and the 
composite end point of death/RRT (p=0.03), however in this study, urinary L-FABP did 
not predict in-hospital mortality (p=0.26).    
 
In a prospective observational study conducted at the Dhaka hospital of International 
centre for Diarrhoeal Disease Research, Bangladesh, in children aged 6-59 months 
admitted with sepsis from April 2010 to December 2011, to study the utility of urinary L-
FABP as a mortality predictor in <5 year old children with sepsis, showed that the first 
urine L-FABP ≥ 370ng/ml (RR 2.76 ;95% CI:1.22-6.25), was identified as a significant 
risk factor of mortality in children with sepsis. Diagnostic performance of first urine L-
FABP was analysed using ROC-AUC and was found to be 0.647(95% CI: 0.500-0/795), 
which showed that urinary L-FABP may be a useful predictor of mortality in septic 
children. (44)  
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A meta-analysis of the performance of urinary liver-type fatty acid binding protein in 
acute kidney injury was studied in humans ,which included 15 prospective cohort and 2 
case-control studies of which only 7 cohort studies were meta-analysed, the results were 
published in 2013 which estimated the sensitivity of urinary L-FABP level for 
diagnosis of AKI as 74.5% (95% CI: 60.4%-84.8%), specificity was 77.6%(95% CI: 
61.5-88.2%). The estimated level of urinary  L-FABP for predicting dialysis 
requirement was 69.1%(95% CI:34.6-90.5%) and specificity was 42.7%(95% 
CI:3.1-94.5%), for in-hospital mortality sensitivity and specificity were 93.2%(95% 
CI:66.2%-99.0%) and 78.8%(95% CI:27%-97.4%).  (43) 
Although urinary L-FABP may be a promising biomarker for early detection of AKI and 
in-hospital mortality, its potential value needs to be validated in large studies and across a 
broader spectrum of clinical settings.(43)   
CONCLUSION: 
AKI is a significant clinical challenge for clinicians. Although sepsis associated AKI is a 
unique subset of all AKI, there is an incomplete understanding of its complex 
pathophysiology. SA-AKI contributes to a higher burden of morbidity and mortality in 
children with critical illness. Advancements have been made for development of robust 
and validated tools including discovery of novel biomarkers to enable early detection of 
renal injury for prevention and treatment of AKI.    
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METHODOLOGY:  
Study design: This study  is  a prospective  observational study 
Setting: This study was undertaken in Child health department - Paediatric ICU/HDU,  
including paediatric wards, at  Christian Medical college, Vellore, India.  
Period of recruitment:  Enrolment of study  participants  was  done  between January  
2017 and August 2017. Enrolled patients were  followed up during their entire period of  
admission.  
Children of age 1 month to 19 years who were diagnosed with severe sepsis, who  
fulfilled the inclusion criteria and did not  have any exclusion criteria, after appropriate  
written parental consent were included in the study.    
Data collection:   
Enrollment was done within 24 hours of admission. A case report form was filled which   
included their demographic details, clinical  history and physical examination. On  
enrolment, a urine specimen was  collected for L-FABP measurement. The  daily clinical  
progress was monitored which included monitoring of urine output, clinical parameters,  
need for ventilation, inotropic support, blood products  support and other complications.   
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The biochemical and laboratory parameters done every day was also recorded in the case  
report form which included daily monitoring of creatinine as  well. Repeat urine L-FABP  
was collected after 48 hours of admission. The PELOD score (Paediatric logistic organ  
dysfunction) which assess the severity of organ dysfunction was done every day for the  
first 5 days or till the time of recovery whichever was earlier. The progress was recorded  
in the case report form. Urine L-FABP assay was done at admission and at 48 hours.  
Around 5ml of urine was collected in a container and was stored below -20
ᵒ 
c for  
analysis. A commercial ELISA kit (Hycult Biotech, USA- Cat # HK 404-01) was used to  
process samples following the manufactures’s instructions. The levels are expressed in  
pg/ml.   
Participants: 
Inclusion criteria:  Diagnosis of severe sepsis as per International Pediatric sepsis 
consensus conference :   
The criteria for severe sepsis include : 
Sepsis- Systemic inflammatory response syndrome  + evidence of suspected/proven 
infection 
SIRS – 1. Tachycardia – HR > 2SD above normal for age 
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             2. Tachypnoea – RR >2 SD above normal for age or need for mechanical 
ventilation 
             3. Abnormal temperature – Fever (>38.5 ᵒC) or hypothermia (<36 ᵒC) 
             4. Abnormal leucocyte profile  
The operational definition of severe sepsis modified for our study included : 
SIRS with evidence of infection (suspected/proven) and requirement of  inotropic 
support after administration of 2 fluid bolus.  
 
Exclusion criteria: 
 Children who did not  fulfill study criteria 
 
 Children with pre-existing renal disease    
 
 
   Variables: 
 
 The data entry was done using Epidata and data analysis was be carried out using 
SPSS16.0. Descriptive statistics was be reported using Frequency and Percentage for 
categorical variable as sex, gender etc. Continuous variables were reported using Mean ± 
SD. Categorical variables were analyzed using Chi square /Fisher exact test. Two 
independent sample t test were  done for comparing Continuous variables after checking 
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for normality.  
Data sources/ measurement: 
The variables to be noted and analyzed are given in the case report form. The data source 
for clinical information was taken from the medical record of the patient (i.e. in patient 
record or from Clinical work station). The L-FABP ELISA was be done as part of the 
study in the Nephrology lab and analysis obtained from there.   
Study size: 
The sample size is based on the prevalence of sepsis which includes cases with  both AKI 
and Non-AKI –    
Single Proportion - Absolute Precision 
Expected  Proportion 0.3 
  Precision (%) 10 
  Desired confidence level  (1- alpha) % 95 
  Required sample size 61 
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STROBE DIAGRAM :       
 
   
 
 
 
 
 
Diagnosed severe sepsis = 49 
Excluded 2 
 Died within a few hours 
of admission 
Children followed up =47 
Included for analysis = 47 
Pediatric ICU admissions Jan 2017-
Aug 2017 = 650 
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RESULTS:   
There were 650 admissions to the Pediatric Intensive care unit during the study period 
between January 2017 and August 2017.   
Of these, 47(7.2%) had severe sepsis. These formed the study group which was evaluated 
further. 
Of the 47 children with severe sepsis, 25/47(53.1%) had AKI. Two were excluded from 
analysis as they died within a few hours of admission and hence could not be followed 
up. 
 
DEMOGRAPHIC DATA: 
The profile of the study group based on age, sex and domiciliary distribution is given 
below.   
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CHARACTER NUMBER  n=47 PERCENTAGE(%) 
1.Age    1-5 years 
 
              10-15 years 
 
              5-10 years 
 
             <1 year 
 
             >15 years 
22 
 
9 
 
8 
 
6 
 
2 
46.8 
 
19.1 
 
17 
 
12.7 
 
4.3 
2.Sex 
 
             Male 
 
 
             Female 
 
 
24 
 
 
23 
 
 
51.1 
 
 
48.9 
3.Domicile 
 
            Tamil Nadu 
 
            Andhra Pradesh 
 
            Other states  
 
 
36 
 
6 
 
5 
 
 
 
 
76.6 
 
12.8 
 
10.6 
TABLE 1.  DEMOGRAPHY 
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Majority of the children were between 1-5 years (22/47- 46.8 %) followed by 9/47 - 
19.1% in the 10-15 year age group.  
There were 24 males (51.1 %) and 23 Females   (48.9%) M:F was 1:1. 
 Majority of the patients were from the state of Tamil Nadu 36/47 (76.1%) 
 
 
FIGURE 1.1 
 
Among 47 children, 24 were males(51.1%) and 23 were females(48.9%)  
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FIGURE 1.2 
 
Among 47 children with Severe sepsis, 6(12.8%) were under 1 year of age 
Majority of children were between 1- 5 years of age – 22/47 (46.8%) 
Between 5-10 years  there were 8/47(17%) 
Between 10-15 years there were  9/47 (19.1%) and 2/47 were >15 years (4.3%).  
 
 
 
53 
 
 
FIGURE 1.3  
 
 
More than half of the population (36/47) were fom Tamil Nadu(76.6%);  6/47 
(12.8%)were from Andhra Pradesh  while 5/47 (10.6%) were from other states.   
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SYMPTOMATOLOGY AT PRESENTATION:   
CHARACTER NUMBER(n=47) PERCENTAGE(%) 
1.Fever 36 76.6 
2.Altered sensorium 21 44.7 
3.Seizures 14 29.8 
4.Decreased urine output 2 4.3 
5.Bleeding manifestation 2 4.3 
6. Rash 1 2.1 
TABLE 2.  
 
 
FIGURE 2 
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Fever was the commonest symptom  seen in 36/47 (76.6%) of the children followed by 
altered sensorium  in 21/47 (44.7%) and  seizures 14/47 (29.8%). 
The others  in small numbers included  bleeding manifestation 2/47 (4.3%), oliguria 2/47 
(4.3%) and rash 1/47 (2.1%).   
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DURATION OF ILLNESS PRIOR PRESENTATION 
 
DURATION NUMBER n=47 PERCENTAGE % 
 
1-3 days 
 
4-7 days 
 
>7 days 
 
32 
 
13 
 
2 
 
68 
 
27.7 
 
4.3 
   
   
   
TABLE 3. 
 
FIGURE 3. 
 
Majority of the children (32/47- 68%) presented  within 3 days of onset of illness 
The remaining- 13/47(27.7%) presented between  4-7 days. 
Only  2/47 (4.3%) presented after being unwell  for >7 days ( 1 week)   
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DURATION OF HOSPITALISATION PRIOR TO ONSET OF  SEPSIS: 
 
DURATION NUMBER n=47       PERCENTAGE% 
None 
 
1-3 days 
 
>4 days 
 
 
32 
 
14 
 
1 
   68 
 
  29.7 
 
  2.1 
    
    
TABLE 4. 
 
 
FIGURE 4. 
 
Only 15/47 were hospitalised prior to onset of severe sepsis. 
 Of these, 14/15 (29.7%) were hospitalised for < 3 days and only 1 (6.6%) child was 
hospitalised for >4 days.   
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VITAL SIGNS AT PRESENTATION: 
VITAL SIGN NUMBER n=47 PERCENTAGE % 
1.Tachypnoea 34 72.3 
2.Hypotension 34 72.3 
3.Low GCS 28 59.5 
4.Hyper/Hypothermia 24 51.1 
5.Tachycardia 21 44.6 
TABLE 5.  
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FIGURE 5.  
 
The most common  signs at presentation was the presence of tachypnoea and hypotension 
in 34/47 (72.3%) .  
 The other common presentations  include low GCS in 28/47 (59.5%), temperature 
instability in 24/47 (51.1%) and  tachycardia in 21/47 (44.6%)  
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INVESTIGATIONS AT PRESENTATION: 
 
INVESTIGATION NUMBER n=47 PERCENTAGE % 
1.Albumin <3.5 g/dl 26 55.3 
2.Liver enzymes >250IU/ml
 
16 34 
3.Anaemia  15 31.9 
4.Thrombocytopenia 14 29.7 
5.PT >22 seconds 8 17 
6.APTT > 57 seconds 8 17 
7.Hyperbilirubinemia 4 8.5 
TABLE 6.  
 
The most common abnormality noted was hypoalbuminemia present in 26/47 (55.3%) of 
children, followed by deranged liver enzymes in 16/47 (34%), anaemia  in 15/47 (31.9%) 
and thrombocytopenia in 14/47  (29.7%) patients. Coagulopathy was present in 8/47 
(17%) and the least common was hyperbilirubinemia seen in 4/47(8.5%).  
 
61 
 
PELOD SCORE VARIABLES (MODS) IN PICU:  
PELOD score assesses the severity of organ dysfunction (MODS) and predicts mortality. 
It was found to be higher in non-survivors as compared to children who improved and 
were discharged. The modified PELOD2 score has 10 variables which includes clinical 
assessment, lab parameters and assessment of each organ involvement.  
 
VARIABLE NUMBER   
n=47 
   % 
1.GCS            
           <8 
 
           >15(normal) 
 
            8-15 
 
 
32 
 
11 
 
4 
 
68 
 
23.4 
 
8.5 
2.Pupillary reaction 
 
             Reactive 
 
             Sluggish 
 
             Fixed 
 
 
 
 
43 
 
3 
 
1 
 
 
91.4 
 
6.3 
 
2.1 
3.Arterial lactate 
 
              1-5 
 
              5-10 
 
              >10 
 
 
38 
 
7 
 
2 
 
 
80.8 
 
14.8 
 
4.2 
4.MAP(mmhg) 
 
           35-44 
 
 
 
36 
 
 
 
76.5 
 
62 
 
            <35 
 
             >45 
7 
 
4 
14.9 
 
8.6 
5.Creatinine (mg/dl) 
 
             <0.7 
 
              0.7-1.2 
 
               >1.2 
 
 
32 
 
11 
 
4 
 
 
68 
 
23.4 
 
8.5 
6.PaO2  (mmhg) 
 
              >61 
 
              <60 
 
 
 
 
40 
 
7 
 
 
85.1 
 
14.8 
7.Paco2 (mmhg) 
 
             >61 
 
             <60 
 
 
0 
 
47 
 
 
 
 
100 
8.Invasive ventilation 
 
            Yes 
 
             No 
 
 
36 
 
11 
 
 
76.6 
 
23.4 
9.Total counts(cells/mm
3
) 
 
           >2000 
 
           <2000 
 
 
42 
 
5 
 
 
89.4 
 
10.6  
10.Platelet count(Lakhs) 
 
           >1.5 
 
           <0.75 
 
            0.75-1.5 
 
 
 
 
24 
 
14 
 
9 
 
 
51.1 
 
29.7 
 
19.1 
TABLE 7. 
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PELOD SCORE - LOW GCS: 
 
 
FIGURE 7.1 
 
 
Of the children with Sepsis, 32/47(68%) had low GCS of <8 and required immediate 
intubation at admission to PICU while 11/47(23.4%) had a normal GCS. 
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PELOD SCORE and PUPILLARY REACTION: 
 
 
 
FIGURE 7.2 
 
 
Most children had normal pupillary reaction -43/47(91.4%) 
Of the total- only 3/47 (6.3%) had sluggishly reactive pupils and 1/47(2.1%) had fixed 
and dilated pupils at admission 
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PELOD SCORE and ARTERIAL LACTATE 
 
FIGURE 7.3 
 
Arterial lactate of <5 was present in 38/47 (80.8%) of children. 
High lactate levels between 5-10 were present in 7(14.8%) and 2/47(4.2%) had> 10 
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PELOD SCORE AND MAP 
 
 
FIGURE 7.4 
 
 
A very low Mean arterial blood pressure (MAP) of<35mmhg was present only in 
4/47(8.6%). 
Majority had a MAP between 35-44 mmhg 36/47 (76.5%) followed by MAP of 45-
65mmhg in 7/47(14.9%).  
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PELOD SCORE and SERUM CREATININE  
 
 
FIGURE 7.5 
 
Serum creatinine was <0.7 in 32 (68%) of children. A higher creatinine in the range 0.7-
1.2mg/dl was seen in 11/47(23.4%) while 4/47 (8.5%) had a creatinine value of 
>1.2mg/dl  
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PELOD SCORE and PaO2 
 
FIGURE 7.6 
 
Majority (40/47- 85.1%) of children had Partial pressure of oxygen (PaO2)>61  
while PaO2 was < 60  was present only in 7/47 (14.8%).  
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PELOD SCORE and INVASIVE VENTILATION 
 
 
FIGURE 7.7 
 
 
Of all the children with Sepsis as many as 36/47 (76.6%) of the children required  
Invasive  ventilation.  
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PELOD SCORE and TOTAL COUNTS: 
 
 
FIGURE 7.8 
 
 
Total counts was <2000 in only 5/47 (10.6%) of children with sepsis 
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FIGURE 7.9 
 
Thrombocytopenia was present in 23/47 (48.9%) children.  
Of these, platelet count of <75,000 was present in 14/23 (60.8%), 9/23 (39.1%) had count 
between 75,000-1,50,000. 
Almost half- 24 47 (51.1%) had a normal platelet count of >1.5 lakhs.  
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PELOD SCORE: 
PELOD SCORE NUMBER(n=47)  
AT ADMISSION 
NUMBER (n=47) 
AT 48 hrs  
<10(n=15) 15/47(31.9%) 18/47(38%) 
10-20(n=26) 26/47(55.3%) 12/47(25.5%) 
>20(n=6) 6/47(12.7%) 12(25.5) 
 
TABLE 8. 
 
FIGURE 8: 
PELOD score was high in non-survivors as compared to survivors 
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A score of >20 was present in 6 patients and mortality was 100% in them 
Score of 10-20 was present in 26, mortality in this group was 61.5% (16/26).   
REQUIREMENT OF INOTROPIC SUPPORT: 
 
INOTROPIC SUPPORT                     NUMBER n=47                    PERCENTAGE% 
 
<72 hours 
 
 
>72 hours 
 
                   30 
 
 
                   17 
 
                63.8 
 
 
                36.1 
   
TABLE 9 
 
FIGURE 9. 
All 47 children needed inotropic support to maintain a normal blood pressure 
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Of these, almost one thirds-17/47 (36.1%) needed inotropic support for   >72 hours  
Two thirds -30/47 (63.8%) needed inotropic support for <72 hours.  
REQUIREMENT OF BLOOD PRODUCTS: 
 
BLOOD PRODUCTS                            NUMBER n=47          PERCENTAGE% 
 
Yes 
 
 
No 
 
                27 
 
 
                20 
 
        57.4 
 
 
        42.5 
   
TABLE 10.  
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FIGURE 10.  
 
Of the total, 27/47 (57.4%) of the children required transfusion of various blood products   
DURATION OF INVASIVE VENTILATION: 
 
INVASIVE 
VENTILATION 
   NUMBER n=38 PERCENTAGE% 
<72 hours 
 
 
>72 hours 
 
 
     22 
 
 
     16 
 
 
       
 
 
 
57.8 
 
 
42.1 
 
   
TABLE 10. 
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FIGURE 10.  
42.1%(16/38) required invasive ventilation for >72hrs, 
57.8%(22/47) required invasive ventilation for only  <72hrs.  
SITES OF CULTURE: 
PRIMARY SEPSIS: 
 NUMBER(n=47)  PERCENTAGE (%) 
Blood culture positivity 13 27.6 
BAL positivity  8 17 
TABLE 11. 
 
SECONDARY SEPSIS: 
 
 NUMBER PERCENTAGE (%) 
Post-op 4 8.5 
Burns  2 4.2 
Central associated blood 
stream infection(CLABSI) 
1 2.1 
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TABLE 12. 
 
Out of the 47 children with severe sepsis  40/47(85.1%)  had primary sepsis,  7/47(14.8%  
%)  had  secondary sepsis. Blood culture was positive only in 13/47 (27.6%) patients. 
 
Of the 14.8%(7/47) patients with secondary sepsis,  4 were post-operative patients, 2 had 
burn injury and 1 was central line associated blood stream infection.(CLABSI).   
The commonest organism was Pseudomonas which was carbapenemase resistant 
organisms (CRO) in  3/13(23%), while 2/13(15.3%) each had MRSA (methicillin 
resistant staphylococcus aureus) and Non-fermenting gram negative bacilli(CRO) the 
species of which was not identified and Candida tropicalis. 
The remaining organisms included 1/13 (7.6%) each of Hemophilus influenza, 
Enterococcus, Klebsiella.  
Bronchoalveolar lavage was positive in 8/47 (17 %).  
These included 2 growths of Candida tropicalis and 1 each of MRSA, alpha hemolytic 
streptococcus, pseudomonas (CRO).   
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ACUTE KIDNEY INJURY: 
The study population of Severe sepsis were assessed for the presence of AKI 
The AKIN Criteria was used to diagnose AKI. 
 The first creatinine value at admission was considered the baseline. All patients included 
in our study were catherised and urine output was monitored every hour. Creatinine 
levels were done everyday thereafter. 
The creatinine clearance was calculated as per the Modified Swartz formula. 
A Urine sample was also collected for our study biomarker at admission and 48 hours 
later.  
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 INCIDENCE OF ACUTE KIDNEY INJURY:  
AKI NUMBER(n=47) 
NORMAL 22(46.8%) 
STAGE 1 15(31.9%) 
STAGE 2 4(8.5%) 
STAGE 3 6 (12.7%)  
TABLE  12. 
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FIGURE 11.  
Amongst children with Severe sepsis   53.1% (25/47) were diagnosed to have AKI. 
Of these 60%(15/25) were in stage 1, 16%(4/25) were in stage 2 and 24% (6/25) were in 
stage 3  
DEMOGRAPHIC CHARACTERS AND  AKI : 
n=47 No AKI 
(n=22)  
Stage1 
(n=15) 
Stage 2 
(n=4) 
Stage 3 
(n=6) 
Age   
<1 year (n=5) 
 
5 
 
1 
 
0 
 
0 
1-5 years(n=23) 9 10 0 4 
>5 years(n= 18) 8 4 4 2 
Sex 
Male(n=23) 
 
11 
 
8 
 
1 
 
3 
Female(n=23) 11 7 3 3 
Normal Nutrition       
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     (n= 24) 9 10 1 4 
 Moderate malnutrition     
(n=10) 
8 
 
0 
 
1 
 
1 
Severe malnutritio(n=13) 5 5 2 1 
TABLE 13.   
Majority of children with AKI were between 1-5 years of age  
M:F ratio was 1:1 
Severe malnutrition was present in 13/45 (28.8 %).  
Of these, 8/13 (61.5%) had AKI. 
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RISK FACTORS OF AKI:  
 
SYMPTOMS 
NO AKI 
(n = 22) 
AKI 
(n = 25) 
1.Fever (n=36) 14/36(38%) 22/36(61%) 
22/25(88%) 
2.Bleeding manifestation (n=2) 1/2(50%) 1/2(50%) 
1/25 (4%) 
3.Oliguria (n=2) 0 2/2(100%) 
2/25(8%) 
4.Seizures (n=14) 6/14(42%) 8/14(57%) 
8/25(32%) 
5.Low GCS (n=21) 9/21(42%) 12/21(57%) 
12/25(48%) 
VITAL SIGNS: 
1.Tachycardia (n=36) 
 
14/36(38%) 
22/36(61%)  
22/25 (88.8%) 
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2.Tachypnea (n=21)  
7/21(33.3%) 
14/21(66.7%) 
14/25 (56%) 
 
TABLE 14. 
 NO AKI 
(n = 22) 
AKI 
(n = 25) 
3.Hypotension (n=34) 15/22(68%) 
15/34(44%) 
19/25(76%) 
19/34(55%) 
LAB PARAMETERS : 
1.Anaemia (n=15) 
9/15(60%) 
9/22(40%) 
6/15(40%) 
6/25(24%) 
2.Thrombocytopenia (n=14) 6/14(42%) 
6/22(27%) 
8/14(57%) 
8/25(32%) 
3.Hyperbilirubinemia (n=7) 4/7(57%) 
4/22(18%) 
3/7(42%) 
3/25(12%) 
4.Elevated liver enzymes(n=7)  4/7(57%) 
4/22(18%) 
3/7(42%) 
3/25(12%) 
5.Coagulopathy (n=8) 3/8(37%) 
3/22(13%) 
5/8(62%)  
5/25(20%) 
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Cont..TABLE 14. 
Among the children with AKI 88% had fever, 56% had tachypnoea, 48% had low GCS 
and only 8% had oliguria.  
When the AKI and non-AKI group were compared we found that in the AKI group 88% 
had tachycardia,  76% had hypotension and 56% had tachypnoea. However amongst 
those who had hypotension there was no difference seen between AKI and non-AKI 
group. 
Amongst those who required prolonged ventilation and prolonged duration of inotropic 
support the risk of AKI was higher (40% Vs 27%) and (48% Vs 22%) respectively.   
 
INTERVENTION: 
1.Ventilation >72hrs (n=16) 
6/16(37%) 
6/22(27%) 
10/16(62%) 
10/25(40%) 
2.Duration of inotropes >72hrs(n=17) 5/17(29%) 
5/22(22%) 
12/17(70%) 
12/25(48%) 
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RISK FACTORS FOR AKI – SYMPTOMS: 
 NORMAL AKI ODDS RATIO  P value 
Age >1 year(n=41) 17/39(43%) 24/39(61%) 7.059 
0.755-65.983 
0.087 
Fever(n=36) 14/36(38.9%) 22/36(61.1%) 4.190 
0.948-18.529 
0.059 
Oliguria(n=2) 0 2/2(100%) 1.957 
1.470-2.604 
0.043 
Seizures(n=14) 6/14(42.9%) 8/14(57.1%) 1.255 
0.356-4.422 
0.724 
Altered 
sensorium(n=21) 
9/21(42.9%) 12/21(57.1%) 1.33 
0.419-4.239 
0.626 
Bleeding 
manifestation(n=2) 
1/2(50%) 1/2(50%) 0.875 
0.051-14.872 
0.926 
TABLE 15. 
Oliguria was the only symptom which significantly increased the risk for AKI 
 ( OR: 1.957; 95% CI :1.470-2.604, p value <0.043).  
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RISK FACTORS FOR AKI –SIGNS: 
 NORMAL AKI ODDS 
RATIO 
P value 
Tachycardia(n=36) 14/36(38.9%) 22/36(61.1%) 4.190 
0.948-18.529 
0.059 
Tachypnoea (n=21) 7/21(33.3%) 14/21(66.7%) 2.727 
0.825-9.011 
0.100 
Hypotension(n=34) 15/34(44%) 19/34(55%) 1.816 
0.274-12.014 
0.536 
Anaemia (n=15) 9/15(60%) 6/15(40%) 0.456 
0.131-1.594 
0.219 
Thrombocytopenia 
(n=14) 
6/14(42%) 8/14(57%) 1.255 
0.356-4.422 
0.724 
Cont..TABLE 15.  
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None of the clinical findings on examination significantly increased the risk for AKI 
RISK FACTORS FOR AKI –LAB FINDINGS 
 NORMAL AKI ODDS RATIO P value 
Hyperbilirubinemia 
(n=7) 
4/7(57%) 3/7(42%) 0.500 
0.370-0.677 
0.556 
Elevated liver 
enzymes(n=7) 
4/7(57%) 3/7(42%) 0.648 
0.150-2.794 
0.662 
Coagulopathy (n=8) 3/8(37%) 5/8(62%)  0.711 
0.162-3.115 
0.651 
Ventilation >72hrs 
(n=16) 
6/16(37%) 10/17(62%) 1.816 
0.474-12.414 
0.351 
Duration of 
inotropes>72hrs(n=17) 
5/17(29%) 12/17(70%) 2.400 
0.202-28.451 
0.488 
Cont..TABLE 15.  
None of the clinical findings on Lab evaluation significantly increased the risk for AKI 
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OUTCOME OF SEVERE SEPSIS: 
OUTCOME NUMBER(n=47) 
DISCHARGED(n=23) 23/47 (48.9%) 
DIED(n=16) 16 /47 (34%) 
DISCHARGED AGAINST MEDICAL 
ADVISE(DAMA)(n=8) 
8/47 (17%) 
TABLE 16. 
 
FIGURE 16. 
23/47(48.9%) were discharged  
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16/47(34%) died, 8/47(17%) were discharged against medical advice.  Children who died 
and DAMA were analysed together as  poor outcome group 24/47(51.1%).  
COMPARISON OF OUTCOME WITH AKI: 
 Discharged 
(n=23) 
Died/DAMA 
(n=24) 
No AKI(n=22) 15/22(68.1%) 7/22 (31.85) 
7/24 (29.2%) 
Stage 1(n=15) 8/15(53.3%) 7 /15 (46.6%) 
7/24 (29.2%) 
Stage 2(n=4) 1/4(25%) 3/4 (75%) 
3/24(12.5%) 
Stage 3(n=6) 0 6/100 (100%) 
6/24 (25%) 
TABLE 17.   
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FIG
URE 17.  
The overall mortality amongst children with AKI was 66.7% (16/23) 
 There was no difference in the mortality between the different stages of AKI .  
ANALYSIS OF STUDY BIOMARKER - L-FABP :  
There were 49 patients who fulfilled the inclusion criteria for severe sepsis and were 
catherised  for monitoring urine output.  
However 2 patients died within a few hours of admission hence they were excluded from 
study. 
Of the 47 samples collected, the ELISA for L FABP was run on 40 samples. 
These results were subjected to further analysis.  
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L-FABP AT BASELINE:    
RANGE OF L-FABP VALUES AT BASELINE:  
RANGE(ng/dl) NUMBER(n=40) PERCENTAGE % 
0-50 20 50% 
50-150 9 22.5% 
150-500 11 27.5% 
TABLE 19.  
 
 
 
FIGURE 18. 
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L-FABP AT 48 hrs:  
RANGE(ng/dl) NUMBER(n=40) PERCENTAGE % 
0-50 25 62.5% 
50-150 7 17.5% 
150-500 8 20%  
TABLE 20.  
 
 
FIGURE 19. 
 
 
93 
 
L-FABP: AKI Vs NON-AKI 
 
 AKI GROUP NON-AKI GROUP  P VALUE 
L-FABP AT 
BASELINE 
 
MEDIAN (IQR) 
39.42  (7.64 - 190.35)  28.61  (8.04-380.88) 0.778 
L-FABP AT 48 hrs 
 
MEDIAN (IQR) 
24.05  (4.56 – 114.05) 14.61  (10.26- 101.61)  0.946  
 
TABLE 21.   
 
Median L-FABP level at baseline was 1.3 times more in the AKI group compared to the 
Non-AKI group. However this was not statistically significant (p = 0.778) 
The change of L-FABP levels from at baseline to 48hrs also could not  predict AKI  
(p=0.946)  
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L-FABP:  SURVIVORS Vs NON-SURVIVORS:  
 NON-SURVIVORS SURVIVORS P VALUE 
L-FABP AT 
BASELINE 
 
MEDIAN (IQR) 
119.08  (11.50 - 412.76) 21.87  (4.05 – 101.24) 0.048 
L-FABP AT 48 hrs 
 
MEDIAN (IQR) 
22.06  (7.90  - 154.17)  
 
17.95  ( 4.79 – 98.37)  0.667  
 
TABLE 22. 
 
At admission, L-FABP level was able to differentiate survivors and non-survivors with a 
p value of 0.048.  
However at 48 hours there was no difference in L-FABP levels between the survivors and 
non-survivors (p=0.667).  
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COMPARISON OF L-FABP WITH PELOD SCORE  
 
 PELOD >10(n=23) 
 
PELOD <10(n=24) P VALUE 
L-FABP AT 
BASELINE  
 
MEAN ±(SD)  
 
 
 
3.96 (2.46) 
 
 
3.59 (2.04) 
 
 
0.070   
L-FABP AT 48 hrs 
 
MEAN ± (SD)  
2.63 (2.46) 3.45 (2.18) 0.103  
 TABLE 23. 
 
L-FABP was compared with PELOD score for assessing multi-organ dysfunction and 
mortality 
Mean L-FABP levels compared   against PELOD score of >10 could predict multi-organ 
dysfunction (MODS) and mortality.  However it was not statistically significant (p = 
0.07).   
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L-FABP Vs AKI:   ROC CURVE  
            
 
FIGURE 20. 
 
The sensitivity and specificity of L-FABP in diagnosing AKI was 26.1% and 71.4% 
respectively   
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L-FABP WITH MORTALITY 
 
FIGURE   21.  
L-FABP on admission   was found to be a good predictor of mortality with a sensitivity 
of 40% and specificity of 88.2%  
 L-FABP baseline AUC- 0.6910, p value 0.048  
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PELOD Vs MORTALITY 
 
Figure 22. 
 PELOD proved to be a good score for assessing the risk for multi-organ dysfunction and 
predicting mortality. 
AUC- 0.801, p value <0.001 
The sensitivity was 30% and specificity   was   69.6%.  
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PELOD Vs AKI:  
 
Figure 23.  
 
PELOD   was shown to be a useful score  which could predict AKI.  
(AUC-0.729, p value 0.008)   
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DISCUSSION:   
Severe sepsis is one of the most common causes of admission to the Pediatric Intensive 
care unit.  Multi-organ  dysfunction  is  commonly  seen in children  with sepsis, acute  
kidney  injury  being  the major complication   amongst  them.  Early diagnosis of AKI  
may  significantly improve the outcome  and  decrease  mortality. Studies have reported 
that Sepsis-associated AKI contributes to a  higher  burden of mortality and morbidity in 
children with critical  illness.  There are several reports in literature of the   risk factors  
of AKI   and  for  early  recognition  of  renal  injury. There is an ongoing search for a 
good  biomarker which can detect AKI early in the setting of Sepsis associated AKI and 
predict its outcome. 
This   study  is  a  prospective  observational  study  performed in the  11  bedded  
Pediatric  Intensive  Care  unit of  a  tertiary  hospital Christian Medical College Vellore 
from January to August 2017. The profile of children admitted with severe sepsis was 
studied. The standard definition laid by the International   Consensus definition for 
Pediatric  Sepsis was applied. All those children who fulfilled these criteria during the 
study period were recruited. The  incidence, risk  factors and outcome of  acute  kidney  
injury  as  defined  by  the  AKIN criteria was studied  and  compared  to  the  various  
diagnostic  tools  of  acute  kidney  injury. The PELOD (pediatric logistic organ 
dysfunction) score was used to assess the severity of organ dysfunction (MODS)  and 
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assess the risk of mortality in all patients. This score was done every day from the point 
of severe sepsis till the time of discharge or for the first 5 days whichever was earlier. All 
patients were managed as per the surviving sepsis guidelines. The end point of the study 
was when the patient was discharged/ died.  
INCIDENCE OF SEVERE SEPSIS: 
The number  of  admissions to the  Pediatric  Intensive  Care  Unit during  the  study  
period between January  2017 and August 2017  was 650. Of the total number of 
admissions,  49 (7.5%)  had  severe  sepsis.  Excluding 2  children who died within  12  
hours  of  admission  without any recorded  urine  output, we had  47  children  who  
formed  the  study  group. This group was statistically analysed.  
The incidence of severe sepsis during this period was 7.5%. This was compared with 
other studies reported in literature. Rakesh  Lodha et al in a study done in PICU in Delhi, 
observed  that  the  incidence  of  severe sepsis  and  septic  shock  was  relatively  low  in 
children  admitted  in the western pediatric intensive care units(2-4%), but  the figures  
are  much  higher (40-67%) for Indian PICUs. 
PROFILE OF CHILDREN WITH SEVERE SEPSIS: 
The demographic profile of our patients with severe sepsis was studied. It was noted that 
46.8% (22/47) were between 1-5 years of age, 40.4% (19/47) were   above 5 years  of age 
and  12.8% (6/47) were under 1 year of age.  The mean age was 56.33 months (range 1- 
230 months).  Male to female   ratio was   almost equal in our study 1:1(Table 1).  In the  
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study by  Kurade et al in  a  PICU in Maharashtra, over a period of 3 years, children aged 
1 month to 18 years with septic shock were analysed. Of these, 56.3% (53/1035) had 
septic shock. The mean age was 3 years (range 1m-14 yrs). They reported majority of the 
children to be infants (25/43 (48.83%)). Children over 1 year constituted 18/43 (41.8%) 
of the remaining. The Male-female ratio in their study was also 1:1:1. While their study 
reported sepsis in predominantly infants, our study reported higher incidence in children 
between 1-5 years. The reason for this is not very clear but could be due to differences in 
the disease profile at different places and times of the year. While our study was limited 
to 7 months, Kurade et al studied Sepsis over a 3 year duration allowing for a more varied 
disease profile. In the previously published study by Agarwal et al on the clinical profile 
and outcome of acute renal failure in south Indian children from our centre in 2003, 44 
children (22%) had proven sepsis and another 22% were suspected to have sepsis. 
Presentation with septic shock was noted in 45% of the patients.  
Almost 2/3
rd
 of the children 36 (76.6%) of the children were from Tamil Nadu, 6(12.8%) 
were from Andhra Pradesh and 5(10.6%) were from other states of India.  
The association of nutritional status with the outcome of severe sepsis was also studied. 
We found that 24/47(51.1%) children had  normal nutritional status. 21.1% (10/47) had  
moderate malnutrition as defined by WHO classification based on standard deviation 
scores and 27.6%(13/47) had severe malnutrition. Almost half of the patient population 
had malnutrition in our study (48.9%) 23/47. (Table 13).  
103 
 
Clinical presentation and symptoms with which the children were brought to hospital was 
looked at. Fever was the commonest symptom in our study noted in 76.6%(36/47)  of 
children followed by  altered sensorium in 44.7%( 21/47), seizures 29.8%(14), bleeding 
manifestations  4.3% (2), decreased urine output 4.3% (2) and rash 2.1%(1) (Table  2 
&Fig 2). Mean duration of symptoms was 5.5 days. A similar observation was reported 
by Kurade et al in his study where fever was the commonest presenting symptom in 
27(62.79%) followed by altered mental status in 13(30.23%). Others included 
breathlessness in 23.25%, cough in 18.60%, vomiting and abdominal distension in 9.3% 
each.  Mean duration of symptoms was 6.4 days in their study.  
The various clinical signs at presentation in our study included tachycardia, tachypnea, 
hypotension, low GCS and temperature instability. Of these tachypnea and hypotension 
were the commonest sign which was seen in 72.3% (34/47) each.  This was followed by 
low GCS 59.5% (28/47), hyper/hypothermia 51.1% (24/47) and tachycardia 44.6% 
(21/47).( Table 5 &Fig 5). Similarly in the Kurade et al study, hypotension was the 
commonest clinical finding reported in 81.39% (35/43),  tachycardia  and   tachypnea  in  
74.41%(32/43) each  and  temperature instability in 62.79%(27/43), and respectively. The 
above mentioned presenting symptoms were statistically analysed age >1 year 
41/47(OR:7.059;95% CI:0.755-65.983), fever present in  36/47(OR:4.190;95% CI:0.948-
18.529), oliguria present in 2(OR:1.957;95%CI:1.470-2.604), seizures present in 
14/47(OR:1.255;95% CI:0.356-4.422), altered sensorium in 21/47(OR:1.33;95% 
CI:0.419-4.239), bleeding manifestation present in 2/47(OR:0.875;95%CI:0.051-14.872). 
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(Table 15).  However it was found that only oliguria (OR 1.957; 95% CI: 1.470-2.604), 
was found to be statistically significant in our study. (Table 15).   
The various investigations at presentation were analysed. The commonest finding was of 
hypoalbuminemia in 55.3% (26/47) of the children. This was closely followed by 
anaemia in  31.9%(15/47),grossly deranged liver enzymes in 34%(16/47), 
thrombocytopenia  in 29.7%(14/47) and coagulopathy (PT>22secs, APTT> 57 secs) in 
17%(8/47).  Leucopenia was present in 10.6% (5/47) and elevated total bilirubin 
(>4mg/dl) levels  was present in 6.3%(3/47), Mean leucocyte count was 12,149(5900-
18,082)/ mm
3
(Table 6).  Deranged renal function tests was present in as many as 
15/47(31.9%). In the Kurade et al study  deranged liver enzymes was present in 86.04%,  
coagulopathy was seen in 60.41%, thrombocytopenia in 55.81%, anaemia in 27(62.7%), 
leucopenia in 13.95% and the least common was deranged renal function tests present in 
6(13.95%). These results are quite in contrast to what we found in our study.    
In our study, the following  parameters were studied and were statistically analysed to 
look for significance, tachycardia present in 36/47(OR:4.19;95% CI: 0.948-18.529), 
tachypnea present in 21/47(OR:2.727;95% CI:0.825-9.011), hypotension present in 
24/47(OR:1.816;95% CI:0.274-12.014), temperature instability present in 
36/47(OR:4.190;95% CI:0.948-18.529), GCS<15 present in 25/47(OR:1.33; 95% 
CI:0.419-4.239), anaemia present in 15/47(OR:0.456 ; 95% CI:0.131-1.594), 
thrombocytopenia was present in 14/47(OR:1.255; 95% CI:0.356-4.422), elevated liver 
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enzymes present in 38/47(0.648; 95% CI:0.150-2.794). (Table 15). None of the above 
parameters were found to be statistically significant in our study.  
In the study done by H.I. Rady et al in PICU in Mounira Pediatric hospital, Cairo, it was 
found that the mortality was increased in patients with fever and hypothermia (OR-5.9; 
specificity 99.4). Mortality was high with deranged liver enzymes >250IU/L (OR-3.6; 
ALT 95% CI: 47.86-155) and was double in patients with PT>22 secs or PTT > 57secs  
and was 100% in patients who needed anti-coagulation(post-cannulation thrombosis).  
However of these, none of the lab parameters were found to be statistically significant in 
our study. Bailey et al has shown that coagulopathy was a risk factor for acute Kidney 
injury and not as a predictor of outcome in children with shock. In our study 3 children 
required anti-coagulation due to post-cannulation thrombosis and mortality was 100% in 
them.  
All 47 children required inotropic support to maintain a normal blood pressure in our 
study. Of these, 63.8% (30/47) children required inotropic support for < 72hrs and  
36.1% (17/47) required  for > 72 hours. Of the 47 children, almost half 46.9% (22/47) 
required ventilation for <72 hours, one third 34% (16/47) required ventilation for >72 
hours. Prolonged need for inotropic support (OR:2.4;95%CI:0.202-28.451) and invasive  
ventilator support (OR:0.508;95% CI:0.122-2.107) were  management strategies 
associated with poor outcome. However in our study they were not statistically 
significant.(Table 15).  
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The mortality of severe sepsis in our study group was 51.1% (24/47) (comprising of 
children who died and were discharged against medical advice). In the Kurade et al study 
the mortality rate was higher at 60.46%. The literature reports high mortality rate of over 
50% in most pediatric patients with septic shock. An Indian study from PGI, Chandigarh 
also reported high (65.8%) mortality rate in fluid refractory septic shock.  
In another study done by Gurpreet et al in a PICU in Haryana noted a mortality rate of 
45%, in our study the mortality rate was 51.1%.  The  higher  mortality rate  was  
probably  due to  the fact  that our  centre  being  the prime referral  centre for sick 
patients from  surrounding districts,  the patient  population caters  to  all  strata  of  
socioeconomic  status  of  both  rural  and  urban  districts  of  Tamil Nadu. Other Indian 
studies have reported mortality rates of 47% from Punjab, 50% from AIIMS, Delhi, 58% 
from Rohtak, Haryana. Our findings are similar to other Indian studies suggesting a 
severe adverse outcome irrespective of the underlying predisposing factors and quality of 
critical care available. Rica et al in his study on the epidemiologic trends of severe sepsis 
in western countries observed a mortality rate ranging between 20-50%, In the US, 
mortality due to severe sepsis had a relative reduction from 51% to 24%. French ICUs 
report a mortality rate ranging from 35% to 56%.  Recent retrospective studies from 
Australia and New Zealand reported a mortality rate between 18.4 % -35%.   
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INCIDENCE OF ACUTE KIDNEY INJURY: 
The incidence of Acute Kidney injury in children with severe sepsis in our study was 
53.1% (25/47). Of the 25 with acute kidney injury classified as per the AKIN criteria , 
31.9%(15/47) were in Stage 1,  8.5%(4/47) were in Stage 2 and 12.8%(6/47) were in 
Stage 3(Figure 12 ).  Overall risk of acute kidney injury in our Pediatric Intensive care 
unit during the eight month period was about 3.8%(25/650). The mortality rate in 
children with sepsis associated AKI (SA-AKI) in our study was 16/24 (66.7%).  
Prowle et al reported that sepsis associated acute kidney injury accounted for 50% of all 
cases of AKI in ICU. He stated that 50% of patients with sepsis associated AKI survive 
to hospital discharge and among those who survive approximately 85-90% recover to 
dialysis independence. In our study similar trend was observed, 50% of them with SA-
AKI survived and mortality was 50%.  
Devarajan et al did a retrospective study in Cincinnati Children’s Hospital for Acute Care 
Nephrology on 77 children with sepsis associated AKI. They noted that the incidence of 
severe AKI was 75% considering all stages taken together. The overall mortality rate was 
33.7%. In this study AKI was defined based on pRIFLE criteria.  
Fitzgerald et al did a prospective cross-sectional point prevalence study done in 128 
PICUs in 26 countries, on children with severe sepsis as part of the Sepsis Prevalence 
Outcomes and Therapies study. They noted that 493 children had severe sepsis out of 
6925 (7.12%) screened over a period of 5 days.  Out of these 493 children 102(21%) had 
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AKI, amongst which 79 %( 391/493) had stage 1 AKI and 20.6% (102/493) had stage 2-
3,   based on KDIGO criteria. The mortality rate in this study was 64%. The authors 
concluded that children with sepsis-associated severe AKI had more than double the odds 
of death or new moderate disability at hospital discharge than children with severe sepsis  
with no/mild AKI. Severe AKI was proven to be an independent risk factor for 
death/moderate disability (adjusted odds ratio, 2.5; 95% CI: 1.5-4.2; p=0.001).  
The varied incidence of AKI in different studies and mortality rate of AKI could be due 
to the different definitions used for the diagnosis of AKI. Our study defined AKI as per 
the AKIN criteria whereas several of the above mentioned studies defined AKI based on 
calculated GFR and baseline creatinine.  However, on several occasions, baseline 
creatinine is unknown in clinical practice.  
 
OUTCOME OF ACUTE KIDNEY INJURY: 
The outcome of acute Kidney injury in our study group was evaluated. Children who died 
and those who were discharged against medical advice were considered together as poor 
outcome and compared against the children who improved and were discharged. 
Mortality among children with Acute Kidney was 64% (16/25). ( Table &Fig 17). The 
overall mortality was 51.1% (24/47) amongst children with severe sepsis in our Pediatric 
Intensive Care unit.  In our study the mortality rate was double (2.02) in children with 
acute kidney as compared to those without acute kidney injury.(66.7% vs 33%).   
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A retrospective analysis by Plotz et al in children admitted with severe septic shock from 
1998 to 2004 in Netherlands showed that mortality rates were significantly higher in the 
acute renal failure group as compared to the non acute renal failure group (57.1% vs. 
6.7%).  Our study also reported a very high mortality rate as in the above study. The 
study design was also similar with inclusion criteria of children with fluid and dopamine 
resistant shock and definition of acute renal failure as deterioration of renal function 
including the need for renal replacement therapy.  This may be explained by the fact that  
mortality rate of severe sepsis as such, with or without acute kidney injury in Indian 
population is very high (almost 50%-60%) as compared to the western population(18.5-
34%).  
Plotz B et al in his retrospective descriptive cohort study to evaluate the practicability of 
pRIFLE criteria in diagnosing AKI and analysis of factors associated with poor outcome  
found a five times higher mortality in children with acute kidney injury as compared to 
those without acute kidney injury(25% vs 5%). His study was only on children with 
respiratory failure requiring mechanical ventilation for >4 days.  As our study dealt with 
Sepsis with or without acute kidney injury, mortality is very high compared to theirs.  
Bailey et al did a one year prospective study on all Canadian children admitted into the 
Pediatric intensive care unit found a 11 fold increase in mortality in the AKI group as 
compared to the non AKI group (27.3% vs 2.5%).  He reported that the presence of  
Multi-organ dysfunction and high PRISM scores in the Acute renal failure group could 
have contributed to the higher mortality in the AKI group. Our study showed only a 2 
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times increase in mortality in the acute kidney injury group. The reason for this 
difference could be that our study group included only children with fluid resistant shock. 
In  the SPROUT study Fitzgerald et al studied  children with severe sepsis  and found that 
severe AKI was present in approximately 20% pediatric patients with severe sepsis. The 
study showed that mortality rate in children with severe AKI was more than twice as high 
as those with no/mild AKI (64% vs 30%; p<0.001). Severe AKI was shown to be 
independently associated with death or new moderate disability (adjusted OR, 2.5; 95% 
CI, 1.5-4.2, p=0.001). Our study   reported twice the increased risk of mortality in sepsis 
associated AKI (66.7% Vs 33.3%).   
Alobaidi et al also studied in children with sepsis associated AKI and reported a  higher 
incidence in critically ill children. Another large study done in 57 adult ICUs in Australia 
and New Zealand SA-AKI identified AKI in  11.7%. 
The Beginning Ending Supportive Therapy for the Kidney, a large prospective 
observational study of more than 29,000 patients, reported an AKI incidence of 5.7% 
with SA-AKI being the most common etiology (47.5%). Analysis of  276,731 admissions 
to 170 adult critical care units of the UK Intensive Care National Audit and Research 
Centre identified con-current sepsis and AKI in 8246 ICU admissions in the first 24 
hours. 
Retrospective studies in primarily sepsis cohorts also have reported a high concurrence of 
SA-AKI. More than 60% of 4532 patients with septic shock from 1989 to 2005 suffered 
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AKI.  In another cohort, AKI was present in 17.7% of 722 patients admitted to an ICU 
specifically for infectious disease.  
RISK FACTORS FOR AKI:  
The various demographic characters were analyzed to look for significant risk factors for 
Acute kidney injury.  The mean age of the study group was 52.35months with a range of 
5 months to 18 years in our study (Table 12). Age group between 1-5 years 
(n=14),56%(14/25), was observed as a risk factor for AKI in our study. Fever was a 
common presentation amongst the children with AKI (22/36, 61%), followed by altered 
sensorium 12/21(57%), seizures 8/14(57%), oliguria 2/2(100%) and bleeding 
manifestation 1/2(50%).  Amongst the clinical signs tachypnea was very common in the 
AKI group 14/21(66.7%), followed by tachycardia 22/36(61%), hypotension 19/34(55%). 
Amongst the various lab parameters coagulopathy was commonly present in the AKI 
group 5/8(62%). In the AKI group 10/17(62%) required prolonged invasive ventilator 
support and 12/17(70%) required prolonged duration of inotropic support as compared to 
the non-AKI group (Table 13).  
Amongst the presenting symptoms oliguria (2/47, 4.3%) was considered a statistically 
significant risk factor for AKI (OR: 1.957;95% CI:1.470-2.604). (Table 15). The other 
lab parameters which was statistically analysed were not found to be   significant. 
Simon et al did a study on the incidence, risk factors and outcomes of acute kidney injury 
in critically ill children and observed that AKI occurred in 42% (130 patients) . Of these, 
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55% of the children <2 years had AKI as observed in his study as compared to < 13 years 
(27%) and >13 years( 37%). Bailey et al reported age > 12 years in acute renal failure in 
critically ill children to be a significant predictor of renal failure. In our study, age group 
between 1-5 years (n=14), 56% was considered risk factor for AKI. (Table 13).  
Among the symptoms at presentation, only oliguria (OR: 1.957; 95% CI: 1.470-2.604) 
was found to be a significant risk factor for acute kidney injury.(Table 15). Hypotension, 
tachycardia, tachypnea and temperature instability were analysed and were not found to 
have a significant correlation (Table 15). Thrombocytopenia, abnormal counts, 
coagulopathy and elevated liver enzymes also did not reach statistical significance 
(Table15). Prolonged need for inotropic support>72hrs and invasive ventilator support 
>72hrs also did not show a significant correlation. 
Bailey et al in his study found hypoxemia, hypotension, thrombocytopenia age > 12 years 
and coagulopathy to be significant risk factors for acute renal failure in critically ill 
children.   
Riyuzo et al  studied  the predictive factors of mortality in pediatric patients with acute 
renal injury associated with sepsis and  identified  the risk factors of mortality  as PICU 
length of stay (OR=0.615, SE=0.1377, 95% CI=0.469-0.805, p=0.0004); invasive 
mechanical ventilation (OR=14.599, SE= 1.1178, 95% CI= 1.673-133.7564, p=0.0155); 
need for dialysis(OR =9.714, SE= 0.8088, 95% CI=1.990-47.410, p=0.0049) and 
hypoalbuminemia (OR= 10.484, SE= 1.1147, 95% CI= 1.179-93.200, p=0.035).  
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Medina et al in the Spanish prospective study to analyze the characteristics of acute renal 
failure in critically ill children found hypovolemia (50%) and hypotension (37%) as 
significant risk factors.   
DIAGNOSIS OF AKI  
There were 25 patients who fulfilled the diagnostic criteria for AKI. They were eligible 
for testing the various tools for detection of AKI. The mean age group was 52.35 months 
with a range of 5 months-18 years.  There were 12 males (50%) and 13 females (56.5%). 
Male to female ratio was   1:1.1. Mean weight was 18.906 kg with a range of 2.9-51.0 kg. 
Mean height  was  103.13cm with a range of 47cm to  155cm.  
The creatinine in the group ranged from 0.7mg/dl to 3.68 mg/dl with a mean of 
0.6679mg/dl.  Creatinine clearance by Modified Schwartz formula ranged from 22 to 345 
ml/min/1.73 m
2
 with a mean of 120.055. Of the 47 children   analysed 22(46.8%) had 
normal renal functions and 25(53.1%) had acute Kidney injury.  15(31.9%) were in 
stage1, 4 (8.5%) in stage2, 6(12.8%) were in stage 3. The mortality in the AKI group was 
68% (17/25) while the rest 32% (8/25) were discharged with normal renal functions and 
with no residual kidney disease.  
BIOMARKERS FOR SEPSIS ASSOCIATED AKI:  
L-FABP values ranged from 0.7 to 487 ng/dl with a mean of 85ng/dl.  Median L-FABP 
level at baseline was 1.3 times more in the AKI group than in Non-AKI group.  
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However L-FABP levels at baseline and at 48hrs was not a significant predictor of AKI  
( p value 0.778 and 0.946). It had a  26.1% sensitivity and 71.4% specificity in predicting 
AKI.    
At admission, L-FABP level was able to differentiate survivors and non-survivors with a 
p value of 0.048. The L-FABP levels were repeated at  48 hours and was compared 
amongst the survivors and non-survivors. However at 48 hours, when compared between 
the survivors and non survivors, it could not predict mortality (p=0.667). 
L-FABP was also compared with PELOD score for assessing multi-organ dysfunction 
and mortality. Mean L-FABP levels were compared against PELOD score of >10 – 
though it had a fairly good predictability for multi-organ dysfunction (MODS) and 
mortality; it   did not reach statistical significancet (p = 0.07).   
An ROC was drawn out and it was demonstared that L-FABP at admission  (baseline)  
was found to be a good predictor of mortality with a sensitivity of 40% and specificity of 
88.2% AUC- 0.6910, p value 0.048.  
Similarly, PELOD score showed a significant ability to predict multi-organ dysfunction 
and mortality.AUC- 0.801, p value <0.001. The sensitivity was 30% and specificity   was   
69.6%. PELOD score was able to significantly predicting AKI. (AUC-0.729, p value 
0.008).  
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In a cross-sectional study Ferguson et al studied the comparative values of multiple 
biomarkers used in the diagnosis of AKI. In a total of 92 patients with established AKI, 
they showed that the diagnostic ability of L-FABP in diagnosing AKI in hospitalized 
patients was very good (ROC-AUC 0.93), as compared to other well-described 
biomarkers of AKI including NGAL (0.92), KIM-1(0.89), NAG(0.89) and IL-18(0.83).  
In this study L-FABP emerged as a significant predictor of RRT (p=0.02) and the 
composite end point of death/RRT (p=0.03).   
 However in our study L-FABP failed to prove its  ability in predicting AKI (p=0.778). 
(Table 22). AUC-ROC curve for L-FABP done at baseline was (0.472) and AUC-ROC 
curve for L-FABP at 48 hr was (0.507). (Figure 20).  
In the Ferrguson et al study, Urine L-FABP ≥ 370ng/ml (RR 2.76 ;95% CI:1.22-6.25), 
was identified as a significant risk factor of mortality in children with sepsis. Diagnostic 
performance of first urine L-FABP was analysed using ROC-AUC and was found to be 
0.647(95% CI: 0.500-0.795), which showed that urinary L-FABP may be a useful 
predictor of mortality in septic children. These results obtained were similar to our study. 
From our study, we can infer that L-FABP   could be a useful biomarker to predict  
mortality and multi-organ dysfunction in children admitted with sepsis. However it was 
not useful in predicting AKI.  PELOD was confirmed to be a good score to assess multi-
organ dysfunction and AKI.  
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SUMMARY: 
1. There were 650 admissions to the PICU during the study period January 2017 to 
August 2017. Following the inclusion criteria, 47 children were studied further. 
2. The incidence of severe sepsis during the study period was 47/650 (7.5%). 
3. The mean age of children in our study was 56.33 months with a range of 1 to 230 
months. Severe sepsis was more common between the age group of 1-5 years 
which constituted 41.8% of the study population.  
4. Male: Female ratio was 1:1.1.  
5. 51% had normal nutritional status. Of the remaining 49%, 21.3% had moderate 
malnutrition and 27.7% had severe malnutrition.   
6. Fever was the commonest symptom in 76.6% followed by altered sensorium 
(44.7%), seizures (29.8%), decreased urine output (4.3%), bleeding manifestation 
(4.3%) and rash (2.1%). 29.7% were hospitalized elsewhere   prior to admission.  
7. Amongst the clinical signs tachypnea and hypotension were present in 72.3% each 
followed by low GCS (59.5%), temperature stability (51.1%) and tachycardia 
(44.6%).  
8. Hypoalbuminemia (55.3%) was the commonest lab parameter, followed by 
elevated liver enzymes (34%), anaemia (31.95), thrombocytopenia (29.7%), 
coagulopathy (17%) and hyperbilirubinemia (8.5%).  
9. Oliguria (odds ratio 1.957, 95%CI: 1.470-2.604, p= 0.043) was a significant risk 
factor for AKI and poor outcome among children with severe sepsis.  
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10.  Of the total, 62% of the children with severe sepsis required invasive ventilation 
for >72 hours and 70% of them required inotropic support for > 72 hours.  
11.  The mortality of severe sepsis in our study group was 51.1% (25/47).  
12. The incidence of Acute Kidney Injury in children with severe sepsis was  53.1% 
(25/47).   
13.  Of the 25 with acute kidney injury classified as per the AKIN criteria , 
31.9%(15/47) were in Stage 1,  8.5%(4/47) were in Stage 2 and 12.8%(6/47) were 
in Stage 3.  
14.  Mortality in children with Acute Kidney Injury was 66.6% (16/24). The overall 
mortality due to SA-AKI was 51% ( 24 / 47 )  
15.  Hypotension (p value 0.536), tachycardia (p value 0.05), lab parameters like 
anaemia (p value 0.219), thrombocytopenia (p value 0.724), coagulopathy ( p 
value 0.651), elevated liver enzymes (p value 0.662) were not found to be 
statistically significant.  
16.  L-FABP at admission (baseline) was 1.3 times more in the AKI group than in 
Non-AKI group  
17. Liver type Fatty Acid Binding Protein (L-FABP) had a sensitivity of 26.1% and 
specificity of 71.4% in diagnosing AKI our study.  
18. At admission, L-FABP level was able to differentiate survivors and non-survivors 
with a p value of 0.048. (p=0.667).  It was a good predictor of mortality with a 
sensitivity of 40% and specificity of 88.2% AUC- 0.6910, p value 0.048.  
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19.   Repeat L FAB levels between survivors and non survivors at 48 hours, L-FABP 
repeat L-FAB levelscould not predict mortality. (p=>0.05) 
20. PELOD score had a significant correlation with the risk for multi-organ 
dysfunction and could predict mortality (AUC- 0.801, p value <0.001). The 
sensitivity was 30% and specificity was   69.6%.   
21. PELOD score was significant in predicting AKI (AUC-0.729, p value 0.008).  
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   CONCLUSION:  
1. Incidence of severe sepsis was 7.5% 
2. The incidence of Sepsis-Associated Acute Kidney Injury was 53.1%.  
3. Mortality of severe sepsis was 51.1%. It remains high inspite of 
improvement in treatment strategies and critical care facilities. 
Mortality in AKI was 2 times more in children with AKI vs non AKI 
(66.7% Vs 33%).  
4. L-FABP was not a good biomarker tool to predict AKI. 
5. Baseline L-FABP level (at admission) was able to differentiate survivors 
and non-survivors with a p value of 0.048, sensitivity of 40% and 
specificity of 88.2%. However repeat L –FAB samples at 48 hours could 
not add benefit as it could not predict non survival. 
6. PELOD was confirmed to be a good score to assess mortality(p value 
<0.001) and AKI (<0.008).  
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LIMITATION: 
1. Small sample size in studying the utility of L-FABP – a larger study may have 
provoded more accurate results. 
2. Doing L- FABP  levels on controls would have added more validity to the study.    
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ANNEXURES:  
Patient Information Sheet – Urinary FABP  in severe  sepsis  
 
Dear Parents , 
 
I am Dr. Merlyn, and I am doing my post- graduation in Pediatrics in Christian Medical College, 
Vellore.  I am doing a research through which we aim to determine the complications associated 
with  severe  sepsis(Infection).  Also  the  cause of death  in sepsis, and the role of a urine  test  
L-FABP(Fatty acid binding protein) in detecting  the  risk  of death earlier.  
 
 
 Myself and my research team would like to invite you to take part in this study.  Once you give 
your consent you will be included in the study .  I would like to ask a few questions pertaining to 
my questionnaire  which would contain general information about your child and also questions 
regarding  cause of  severe infection and  complications. I would collect a urine  sample( after 
admission at 0 hour, then at 24 hours and after 48 hours) of your child at admission that would 
help us with our study.  The sample collected will be processed later  which will help  in   future  
reference  and  study.     
 
What is the purpose of the study? 
 
Severe infection is very common in children and associated with many complications 
and can even lead to death. Hence it is necessary to detect  the  severity  earlier so 
that we can act earlier.  This study will help in  determining the complications  and  
probability of mortality  earlier  by doing  a simple  urine  test at the time of 
admission itself,  to see it the levels  correlate  with  the severity  of the infection.  
 
Why are you invited? 
 
We  would  like to know  the  complications associated with severe infection and the reason for 
such severity only in certain children.  By doing the  special urine  test  earlier during the disease 
course,  and  based on the levels  we  obtain,   we might come to know the severity of  the  
disease condition quite earlier and act earlier. Since your child  is suspected  to have a severe 
infection we would like  your child to participate  in the study.  
 
Do I have to take part? 
 
No. You don’t. You may choose not to have your child participate in this study.Choosing to 
participate or not will not affect either your own or your child's future treatment at the Centre 
here in any way. You and your child will still have all the benefits that would otherwise be 
available at this Centre. 
 
What will happen to me if I take part? 
I would like to ask a few questions pertaining to my proforma  which would contain general 
information about your child and also questions regarding your child’s severe infection and the 
associated complications. I would also be looking at your child’s blood tests and urine  test 
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reports  during admission to determine the status of severity of the infection.  Along with the 
routine urine tests  I would like to collect an extra urine sample for the sepical test that I would 
like to perform pertaining to my study.  The knowledge  gained through this study will help in 
future as  a reference for  early intervention and treatment in children with severe infection.  
What are the possible benefits of the study? 
 
The knowledge obtained from the study will help in future for predicting the  severity of the infection and 
complications and the  chance of mortality so that we can intervene earlier. 
 
Reimbursements 
 
Your daughter/son will not be provided with any payment to take part in the research. 
 
Will my taking part in the study be confidential? 
 
Your individual answers will not be shared with others. The  information that we collect from 
this research project will be kept confidential. Information about your child that will be collected 
for the research prupose will be put away and no-one but the researchers will be able to see it. It 
will not be shared with or given to anyone except the research team. 
 
 
What will happen to the results of the research study? 
At the end of the study, we will be sharing what we have learnt with the community. The 
information that you share about your child   will not  be revealed  outside the research team, and 
nothing will be attributed to him/her by name. We will also publish the results in order that  the 
results  gained  from this  study  will benefit  the others. 
Who to Contact? 
 
If you wish to ask questions later, you may contact:  
Dr. Merlyn Nisha. J 
Department of Pediatrics 
Christian Medical college, 
Vellore. 
0416-2283348/984358731 
Merlynnisha45@gmail.com 
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Informed Consent form to participate in a research study  
 
Study Title: 
Urinary  FABP as a mortality predictor  in children with severe sepsis 
 
Study Number: ____________ 
 
Subject’s Initials: __________________ Subject’s Name: 
_________________________________________ 
 
Date of Birth / Age: ___________________________ 
 
(Subject) 
 
(i) I confirm that I have read and understood the information sheet dated ____________ for the above study. 
 
(ii) I understand that by answering the questions put forward by the doctor, I am giving my consent as a 
participant volunteer in this study and that I am free to withdraw at any time, without giving any 
reason, without my medical care or legal rights being affected. [  ] 
 
(iii) I understand the basic nature of the study and agree that any potential risks are exceedingly small. I also 
understand the potential benefits that might be realized from the successful completion of this study. 
 
(iv) I am aware that the information is being sought in a specific manner so that no identifiers are needed and 
that confidentiality is guaranteed. 
 
(v) I understand that researcher, the Ethics Committee and the regulatory authorities will not need my 
permission to look at my health records both in respect of the current study and any further research 
that may be conducted in relation to it, even if I withdraw from the trial. I agree to this access. 
However, I understand that my identity will not be revealed in any information released to third 
parties or published. [  ] 
 
(vi) I agree not to restrict the use of any data or results that arise from this study provided such a use is only 
for scientific purpose(s). [  ] 
 
(vii) I agree to take part in the above study. [  ] 
 
 
I am aware that certain blood and urine tests will be done at admission  the results of which will be 
analysed. I am also aware that blood and urine samples will be stored for future study and reference. 
  
 
Signature (or Thumb impression) of the Subject/Legally Acceptable  
 
Date: _____/_____/______ 
 
Signatory’s Name: _________________________________         Signature 
Informed Assent Form for Children who are invited to take part in the study(> 8  years) 
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Name of Principle Investigator: Dr.Merlyn Nisha. J 
 
Name of Organization: Christian Medical College,Vellore 
 
Name of the research:   urinary  FABP  as  a predictor of mortality  in children  
with severe sepsis 
 
 
I have read the information sheet . I have had my questions answered and 
know that I can ask questions later if I have them.  
  
 
I agree to take part in the research. 
 
 
 
 
 
Print name of child ___________________ 
Signature of child: ____________________ 
Date:________________ 
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day/month/year 
  
In case of any query kindly contact 
Dr.Merlyn Nisha 
Department of Paediatrics 
Christian Medical college 
Vellore 
0416-2283348/9843587231 
ஆய்வுதலைப்பு: urinary  FABP  as  a predictor of mortality  in children  with 
severe sepsis 
 
 
ஆராய்ச்சிஎண்: ____________ 
 
பொருளின்தலைப்பெழுத்துக்கள்:, __________________  
பொருளின்பெயர்: _________________________________________ 
 
(தலைப்பு) 
 
நான்இந்ததகவலைவாசிதுக்ககாண்டேன்.(எனக்குஇந்ததகவல்வாசிக்கப்பட்ேது).என்டகள்
விகளுக்குபதில்கபற்றுக்ககாண்டேன். இன்னும் இருந்தால் நான் பின்னர் ககள்விகளை 
ககட்க முடியும் என்று எனக்கு ததரியும். 
 
நான் ஆ஭ாய்ச்சியில் பங்ககற்க ஒப்புக்தகாள்கிகமன் . 
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குழந்ளத அச்சிட தப஬ர் ___________________ 
குழந்ளத ளகத஬ாப்பம்: ____________________ 
நாள்: _______________ நாள் / ஫ாதம் / ஆண்டு 
PROFORMA: 
                                      L-FABP AS A MORTALITY PREDICTOR IN SEVERE SEPSIS  
Name-                                                                                  Hospital number -                                               Date- 
Sex-  Boy / Girl                                                                    Date of birth -                        Age in years   -                               
Address-       
 Weight -         kg                                                                  Height-       cm    
MUAC :  
Prior hospitalization – Yes / No-           if Yes -      days  
 
HISTORY: 
1.FEVER  -                                YES                             NO 
2. DURATION                        DAYS 
3.RASH                                    YES                             NO 
5.BLEEDING MANIFESTATION          YES                     NO  
6. DECREASED URINE     OUTPUT              YES                   NO  
7.BREATHLESSNESS                    YES                   NO 
8.IMPAIRMENT IN SENSORIUM                    YES                     NO 
9.  SEIZURES                    YES                   NO 
DAILY  MONITORING SHEET: 
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   AT 
ADMISSION(WARD) 
 DAY 
1 
DAY 
2 
DAY 
3 
DAY 
4 
DAY 
5 
     
TEMPERATURE            
 
HEMOGLOBIN/PCV 
           
PLATELETS            
PT            
APTT            
TOTAL/DB BILIRUBIN 
 
           
ALBUMIN            
OT/PT            
CRP            
SODIUM            
POTASSIUM            
CREATININE            
UREA            
INOTROPES            
BLOOD 
TRANSFUSION 
           
URINE OUTPUT            
CREAT.  
CLEARANCE(SWARTZ) 
           
 
 
14 . SHIFTED TO PICU/HDU                           YES                           NO 
 
15.  ON DAY ----------------  OF ADMISSION    
 
16. PELOD SCORE 
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ORGAN DYSFUNCTION AND 
VARIABLE
SCORE
DAY 1
SCORE 
DAY 2
SCORE
DAY 3
SCORE
DAY 4
SCORE 
DAY 5
NEUROLOGIC:
1. GCS
2.PUPILLARY REACTION
CARDIOVASCULAR
1.  LACTATEMIA (mmol/L)
2.  MAP mmhg
RENAL
1. CREATININE
RESPIRATORY
1. PaO2
2.PaCo2
3. INVASIVE VENTILATION
BLOOD
1. TOTAL COUNTS
2.PLATELETS
 
 
 
17.Urinary FABP   at admission-                 ng/dl 
18.   CORRELATION  OF URINARY FABP AND PELOD SCORE:  
PELOD  SCORE  
URINARY  FABP( 0 HOUR SAMPLE)  
 
19. OUTCOME   -Death/discharged   
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slno 
Specimen 
ID Time name hospno date bleeding urine Remark 
19 P39-MN-01 First sample nithrathan 528634g 1/9/2017 2 2   
  P39-MN-02 
Second 
sample nithrathan 528634g 1/9/2017       
21 P39-MN-03 First sample karthikeyan 541480g 1/11/2017 2 2   
  P39-MN-04 
Second 
sample karthikeyan 541480g 1/11/2017       
15 P39-MN-05 First sample dhiya 542260g 1/21/2017 2 2   
  P39-MN-06 
Second 
sample dhiya 542260g 1/21/2017       
22 P39-MN-07 First sample jabastin 690302g 1/22/2017 2 2   
  P39-MN-08 
Second 
sample jabastin 690302g 1/22/2017       
27 P39-MN-09 First sample gowtheeswaran 083010f 1/23/2017 2 2   
  P39-MN-10 
Second 
sample gowtheeswaran 083010f 1/23/2017       
11 P39-MN-11 First sample jeevaraj 528711g 1/24/2017 2 2   
  P39-MN-12 
Second 
sample jeevaraj 528711g 1/24/2017       
12 P39-MN-13 First sample srinithi 543017g 1/27/2017 2 2   
  P39-MN-14 
Second 
sample srinithi 543017g 1/27/2017       
14 P39-MN-15 First sample hari priya 551070g 1/28/2017 2 2   
  P39-MN-16 
Second 
sample hari priya 551070g 1/28/2017       
40 P39-MN-17 First sample shreven durga 696656f 1/29/2017 2 2   
  P39-MN-18 
Second 
sample shreven durga 696656f 1/29/2017       
46 P39-MN-19 First sample baby of gayathri 515841g 2/10/2017 2 2   
  P39-MN-20 
Second 
sample baby of gayathri 515841g 2/10/2017       
5 P39-MN-21 First sample deepika 365173d 2/16/2017 2 2   
  P39-MN-22 
Second 
sample deepika 365173d 2/16/2017       
45 P39-MN-23 First sample sakthivel 192055d 2/17/2017 2 1   
  P39-MN-24 
Second 
sample sakthivel 192055d 2/17/2017       
28 P39-MN-25 First sample balaji 551876g 2/18/2017 2 2   
  P39-MN-26 
Second 
sample balaji 551876g 2/18/2017       
38 P39-MN-27 First sample tharuniya 551837g 2/20/2017 2 2   
  P39-MN-28 Second tharuniya 551837g 2/20/2017       
136 
 
sample 
7 P39-MN-29 First sample mohammed hayath 551902g 2/20/2017 2 2   
  P39-MN-30 
Second 
sample mohammed hayath 551902g 2/20/2017       
16 P39-MN-31 First sample dharani 551547g 3/4/2017 2 2   
  P39-MN-32 
Second 
sample dharani 551547g 3/4/2017       
13 P39-MN-33 First sample varshini 551574g 3/5/2017 2 2   
  P39-MN-34 
Second 
sample varshini 551574g 3/5/2017       
30 P39-MN-35 First sample krithik roshan 253056g 3/6/2017 2 2   
  P39-MN-36 
Second 
sample krithik roshan 253056g 3/6/2017       
6 P39-MN-37 First sample haniya 547166g 3/13/2017 2 2   
  P39-MN-38 
Second 
sample haniya 547166g 3/13/2017       
26 P39-MN-39 First sample priyadarshini 551316g 3/15/2017 2 2   
  P39-MN-40 
Second 
sample priyadarshini 551316g 3/15/2017       
9 P39-MN-41 First sample yamgo gamlin 835107g 3/30/2017 2 2   
  P39-MN-42 
Second 
sample yamgo gamlin 835107g 3/30/2017       
39 P39-MN-43 First sample atiya 528828g 4/1/2017 2 2   
  P39-MN-44 
Second 
sample atiya 528828g 4/1/2017       
17 P39-MN-45 First sample wasim 528908g 4/4/2017 2 2   
  P39-MN-46 
Second 
sample wasim 528908g 4/4/2017       
43 P39-MN-47 First sample lithiya sri 567596g 4/10/2017 2 2   
  P39-MN-48 
Second 
sample lithiya sri 567596g 4/10/2017       
18 P39-MN-49 First sample sumily dey 813438g 4/25/2017 2 2   
  P39-MN-50 
Second 
sample sumily dey 813438g 4/25/2017       
20 P39-MN-51 First sample ridha taslen 957581f 5/18/2017 2 2   
  P39-MN-52 
Second 
sample ridha taslen 957581f 5/18/2017       
47 P39-MN-53 First sample lokeshwaran 556374g 5/24/2017 2 2   
  P39-MN-54 
Second 
sample lokeshwaran 556374g 5/24/2017       
25 P39-MN-55 First sample kavin 528035g 5/30/2017 2 2   
  P39-MN-56 
Second 
sample kavin 528035g 5/30/2017       
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1 P39-MN-57 First sample baby of vijayalakshmi 700215g 6/1/2017 2 2   
  P39-MN-58 
Second 
sample baby of vijayalakshmi 700215g 6/1/2017       
24 P39-MN-59 First sample muzahidul 556361g 6/3/2017 2 2   
  P39-MN-60 
Second 
sample muzahidul 556361g 6/3/2017       
35 P39-MN-61 First sample lesha 556578g 6/4/2017 2 2   
  P39-MN-62 
Second 
sample lesha 556578g 6/4/2017       
34 P39-MN-63 First sample lakshitha 556590g 6/5/2017 1 2   
  P39-MN-64 
Second 
sample lakshitha 556590g 6/5/2017       
3 P39-MN-65 First sample narasimah 556611g 6/6/2017 2 2   
  P39-MN-66 
Second 
sample narasimah 556611g 6/6/2017       
33 P39-MN-67 First sample akash 638104c 6/6/2017 2 2   
  P39-MN-68 
Second 
sample akash 638104c 6/6/2017       
32 P39-MN-69 First sample tharunika 999056f 6/10/2017 2 2   
  P39-MN-70 
Second 
sample tharunika 999056f 6/10/2017       
8 P39-MN-71 First sample rithika 556570g 6/12/2017 2 2   
  P39-MN-72 
Second 
sample rithika 556570g 6/12/2017       
2 P39-MN-73 First sample sai kiruthik 557806g 6/13/2017 2 2   
  P39-MN-74 
Second 
sample sai kiruthik 557806g 6/13/2017       
41 P39-MN-75 First sample bismina 744822g 6/21/2017 2 2   
  P39-MN-76 
Second 
sample bismina 744822g 6/21/2017       
4 P39-MN-77 First sample issa marya 321702g 6/24/2017 2 2   
  P39-MN-78 
Second 
sample issa marya 321702g 6/24/2017       
10 P39-MN-79 First sample jeyan 556809g 6/24/2017 2 2   
  P39-MN-80 
Second 
sample jeyan 556809g 6/24/2017       
23 P39-MN-81 First sample hemsai 577218d 6/26/2017 2 2   
  P39-MN-82 
Second 
sample hemsai 577218d 6/26/2017       
29 P39-MN-83 First sample pirunishka 906177f 6/28/2017 1 1   
  P39-MN-84 
Second 
sample pirunishka 906177f 6/28/2017       
42 P39-MN-85 First sample brindha 556926g 7/4/2017 2 2   
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  P39-MN-86 
Second 
sample brindha 556926g 7/4/2017       
36 P39-MN-87 First sample srija 556961g 7/6/2017 2 2   
  P39-MN-88 
Second 
sample srija 556961g 7/6/2017       
44 P39-MN-89 First sample kauveri 556198g 7/10/2017 2 2   
  P39-MN-90 
Second 
sample kauveri 556198g 7/10/2017       
37 P39-MN-91 First sample hemamalini 941946d 7/16/2017 2 2   
  P39-MN-92 
Second 
sample hemamalini 941946d 7/16/2017       
31 P39-MN-93 First sample puvidharan 898987f 7/18/2017 2 2   
  P39-MN-94 
Second 
sample puvidharan 898987f 7/18/2017       
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